

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant..

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 0 997 529 A2**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
03.05.2000 Bulletin 2000/18

(21) Application number: 99306508.5

(22) Date of filing: 18.08.1999

(51) Int Cl.7: **C12N 15/49**, C12N 7/00,
C12N 7/04, C12N 5/10,
A61K 39/21, C07K 14/155,
C07K 16/10

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 24.08.1998 US 97645 P

(83) Declaration under Rule 28(4) EPC (expert
solution)

(71) Applicant: **Pfizer Products Inc.**
Groton, Connecticut 06340 (US)

(72) Inventors:
• **Deng, Ruitang**
Old Lyme, Connecticut 06371 (US)
• **Sheppard, Michael George**
North Stonington, Connecticut 06359 (US)

(74) Representative:
Simpson, Allison Elizabeth Fraser et al
Urquhart-Dykes & Lord,
91 Wimpole Street
London W1M 8AH (GB)

(54) **Feline immunodeficiency virus strain FIV-141 and uses thereof**

(57) The present invention is directed to a novel strain of feline immunodeficiency virus, designated herein as FIV-141, and to attenuated forms of the virus

produced by mutating specific regions of the viral genome. The virus and mutated forms of the virus may be used to induce the production of antibodies to FIV-141, and in vaccines designed to protect cats from FIV.




FIG. 1

EP 0 997 529 A2

DescriptionField of the Invention

5 [0001] The present invention is directed to a novel strain of feline immunodeficiency virus (FIV) and to a variety of mutated forms of this virus. Compositions and methods are disclosed that can be used in the protection of animals from lentiviral associated disease.

Background of the Invention

10

[0002] Feline immunodeficiency virus (FIV) infection in cats results in a disease syndrome that is similar to that caused by human immunodeficiency virus-1 (HIV-1) infection in humans. Disease progression begins with a transient acute phase (8-10 weeks), followed by a prolonged asymptomatic phase (lasting from weeks to years) and a terminal symptomatic phase (Ishida *et al.*, 1990, Jpn. J. Vet. Sci. 52:645-648). Viral load in plasma has been demonstrated to correlate with disease stage in infected cats and can be used to predict disease progression in accelerated FIV infection (Diehl *et al.*, 1996, J. Virol. 70:2503-2507).

15

[0003] Structurally, the FIV provirus contains two long terminal repeats (LTRs), one at either end of the genome (Talbot *et al.*, 1989, Proc. Nat'l Acad. Sci. USA 86:5743-5747). There are three large open reading frames (Gag (group antigens); Pol (polymerase); and ENV (envelope)) and three small open reading frames encoding regulatory proteins (Rev (regulator of expression of virion, a protein that binds to "RRE" elements present in all viral transcripts and promotes their translocation from the nucleus to the cytoplasm of infected host cells); Vif (virion infectivity factor); and ORF(2) (open reading frame 2)). The Gag precursor polypeptide of FIV is processed into three mature structural proteins: a matrix protein (MA), a capsid protein (CA), and a nucleocapsid protein (NC). The Pol gene encodes four enzymatic proteins: a protease (PR), a reverse transcriptase (RT), a deoxyuridine triphosphatase (DU), and an integrase (IN). Finally, the ENV precursor polypeptide is processed into two envelope proteins: a surface protein (SU) and a transmembrane (TM) protein.

25

[0004] There have been several attempts to develop a safe and effective vaccine to FIV. Matteucci found that cats inoculated with a conventional fixed cell vaccine were protected from challenge with homologous virus despite an apparent absence of neutralizing antibodies after vaccination. Protection was found to be short-lived and difficult to boost (Matteucci *et al.*, 1996, J. Virol. 70:617-622; Matteucci *et al.*, 1997, J. Virol. 71:8368-8376). These results may be contrasted with those of Verschoor, who observed no protection after the administration of a fixed cell vaccine (Verschoor *et al.*, 1995, Vet. Immunol. Immunopathol. 46:139-149).

30

[0005] Another type of conventional vaccine that has been tested is comprised of whole, inactivated FIV virus. Yamamoto reported that greater than 90% of cats administered a vaccine of this type exhibited essentially complete protection against homologous challenge and slight protection against heterologous virus (Yamamoto *et al.*, 1993, J. Virol. 67:601-605). Both humoral and cellular immunity against FIV were induced and a high level of anti-ENV, anti-core and virus neutralizing (VN) antibodies were observed in the vaccinated cats. In contrast, vaccination of cats with inactivated whole FIV incorporated into immune stimulating complexes (ISCOMs) failed to protect animals from homologous challenge (Hosie *et al.*, 1992, Vet. Immunol. Immunopathol. 35:191-197).

35

[0006] Another approach to vaccine development has involved the use of subunit vaccines containing recombinant core protein, synthetic V3 peptides, and recombinant ENV protein (Elyar *et al.*, 1997, Vaccine 15:1437-1444). Although significant levels of antibodies were induced by such vaccines, none were identified that could protect cats against homologous FIV challenge (Huisman *et al.*, 1998, Vaccine 16:181-187; Flynn *et al.*, 1997, J. Virol. 71:7586-7592; Tijhaar *et al.*, 1997, Vaccine 15:587-596). The results suggest that it is likely to be difficult to obtain protective immunity against FIV using subunit type vaccines.

45

[0007] Recently, Cuisinier reported on tests conducted on a DNA vaccine for FIV (Cuisinier *et al.*, 1997, Vaccine 15:1085-1094). Cats were vaccinated with a plasmid carrying FIV structural genes, including ENV and p10. Although strong humoral immune responses were observed, all cats eventually succumbed to homologous challenge.

50

Summary of the Invention

[0008] The present invention is based, in part, upon the isolation and characterization of a new strain of feline immunodeficiency virus, designated herein as FIV-141. The complete genomic sequence of the virus has been determined and is distinct from all other known FIV sequences. A plasmid encoding FIV-141 has been deposited as ATCC No. 203001.

55

A. Compositions and Methods Based Upon the FIV-141 Virus

[0009] In its first aspect, the present invention is directed to a substantially purified FIV-141 virus having a genomic sequence corresponding to that of SEQ ID NO:1, to host cells infected with the virus and to progeny virus produced in the host cells. The term "substantially purified" means that FIV-141 has been separated from all other strains of virus and, particularly, from all other strains of FIV. Host cells that may be used for growing virus include peripheral blood mononuclear cells (PBMCs). Progeny virus may be isolated using standard procedures as discussed below.

[0010] The FIV-141 virus and host cells infected with the virus can be used to infect animals for the purpose of inducing the production of antibodies that react preferentially with one or more strains of FIV. "Preferential binding" of antibodies, as used herein, refers to an antibody having at least a 100-fold greater affinity for FIV than for any other virus or non-FIV protein. Antibodies may be generated in any of the animals commonly used for this purpose (such as, e.g., mice, rabbits, goats, or sheep) but, preferably, antibodies will be made in domestic cats. When virus is used to induce antibody production, it may, if desired, be inactivated prior to infection. Inactivation procedures may involve treating the virus with formalin, paraformaldehyde, phenol, lactopropionate, ultraviolet light, heat, psorlens, platinum complexes, ozone or other viricidal agents. When host cells expressing FIV-141 are used to induce antibody production, the cells may be fixed prior to infection. Typically, this will involve treating the cells with paraformaldehyde as described herein, but other methods may also be employed. Antibodies made to FIV-141 are themselves included within the scope of the invention and may be purified using techniques well known in the art (see, e.g., Harlow *et al.*, 1988, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, N.Y.).

[0011] In another aspect, the invention is directed to a whole virus vaccine comprising inactivated FIV-141 virus. An immune response may be induced in a cat by administering this vaccine at a dosage and for a duration sufficient to induce protective immunity against subsequent infection with FIV-141. Typically, the vaccine will be administered parenterally with two or more inoculations being given at intervals of, e.g., two to eight weeks. The invention also includes a fixed cell vaccine, which is comprised of a host cell infected with the FIV-141 virus. Administration of this vaccine will follow the same general procedures as used for the whole virus vaccine. Standard procedures well known in the art may be used to optimize immunization protocols.

B. Compositions and Methods Based Upon FIV-141 Genomic Nucleic Acid

[0012] In another aspect, the present invention is directed to a substantially purified nucleic acid molecule (DNA or RNA) having a sequence corresponding to that of SEQ ID NO:1. As used in this context, "substantially purified" means that the desired product is essentially free from contaminating cellular components. A "substantially pure" nucleic acid will typically comprise at least 85% of a sample, with greater percentages being preferred. Contaminants may include proteins, carbohydrates or lipids. One method for determining the purity of a nucleic acid is by electrophoresing a preparation in a matrix such as polyacrylamide or agarose. Purity is evidenced by the appearance of a single band after staining. Other methods for assessing purity include chromatography and analytical centrifugation. The FIV-141 nucleic acid may be used in place of the whole virus to transfect host cells and to thereby induce the production of progeny virus or viral proteins.

[0013] The invention also encompasses methods of inducing the production of antibodies to FIV-141 by injecting nucleic acid directly into an animal or by administering host cells transfected with the nucleic acid. As with the procedures discussed above in connection with the whole virus, host cells may be fixed prior to administration. Antibodies may be purified from animals and used in assays designed to detect the presence of FIV in culture medium or in a biological fluid.

[0014] Host cells transfected with FIV-141 genomic DNA may also be used in a vaccine for immunizing cats. If desired, such cells may be fixed to reduce viral infectivity, e.g., by treatment with an agent such as paraformaldehyde. Vaccines made in this manner may be used to induce an immune response in a cat. The vaccine may be administered using a standard immunization protocol optimized for the induction of protective immunity against subsequent infection with FIV-141 or, if desired, some other strain of FIV.

C. Attenuated FIV-141 Virus and Vaccines

[0015] Before a whole virus can be administered to an animal as a vaccine, it must be converted into a non-pathogenic form. As discussed above, this may be accomplished by inactivating the virus or fixing host cells. An alternative method involves introducing mutations into the virus to transform it into an attenuated form. The phrase "attenuated virus" as used in this context, refers to a virus that has substantially reduced infectivity compared to its wild type counterpart. Infectivity may be measured in PBMCs, as described in the Examples section herein below.

[0016] Thus, the invention is directed to an attenuated FIV-141 virus that exhibits significantly reduced infectivity for feline T lymphocytes relative to the wild type (*i.e.*, non-mutated) virus. The attenuated virus is produced by mutating

one or more genes in the FIV-141 genome selected from the group consisting of Vif, MA, ORF(2), ENV, CA, NC, SU, TMf, CT, IN, DU, V3/4, V7/8 and RRE. Appropriate mutations for each of these genes are described herein. Examples of several specific mutations that may be used in making attenuated viruses include MA del, ENV del, V3/4 del, V7/8 del, TMf del, CT del, Vif del, Vifc del, Vifn del, ORF(2) del, CA del, NC del, IN del, DU del, SU del, and RRE del. The invention also encompasses host cells infected with the attenuated virus and the progeny virus produced by such cells. Once produced, the attenuated virus may be purified from host cells using standard procedures.

[0017] Antibody production may be induced by infecting an animal with the attenuated virus or, alternatively, infected host cells may be used. If desired, the virus may be inactivated or the host cells fixed prior to administration to an animal and antibodies may be purified from animals using standard procedures.

[0018] In addition, the invention encompasses a vaccine that utilizes the attenuated whole virus discussed above or a host cell infected with one of these viruses. Again, the attenuated viruses may be inactivated and the host cells may be fixed. Such treatments may provide added assurance that vaccines will not themselves cause infection. Vaccines based upon one or more attenuated FIV-141 viruses may be used to induce protective immunity in a cat. Standard immunization protocols may be followed in administering vaccines so as to optimize the induction of protective immunity against subsequent challenge with FIV-141.

D. Compositions and Methods Based upon Mutated FIV-141 Genomic DNA

[0019] In another aspect, the present invention is directed to a substantially purified FIV-141 nucleic acid (DNA or RNA) having a sequence corresponding to SEQ ID NO:1 but which has been mutated to encode an attenuated virus. Mutations should be to one or more genes selected from the group consisting of Vif, MA, CA, NC, SU, TMf, ORF(2), CT, ENV, Vifn, Vifc, IN, DU, V3/4, V7/8, and RRE, and should be made in such a manner that, upon introduction into a host cell, a virus is made that has significantly reduced infectivity for feline T lymphocytes (or other susceptible cell types) relative to the wild type virus. Examples of several specific mutations that will produce an appropriate attenuated virus are described herein and include: MA del, ENV del, V3/4 del, V7/8 del, TMf del, CT del, Vif del, Vifc del, Vifn del, ORF(2) del, SU del, CA del, NC del, IN del, DU del, and RRE del. The invention includes host cells transfected with the mutated nucleic acid and FIV progeny virus produced by the host cells.

[0020] Also included within the scope of the invention is a method of inducing the production of antibodies to FIV in an animal by injecting either nucleic acid mutated as described above or a host cell that has been transfected with the nucleic acid. If desired, the host cell may be fixed prior to administration. The antibodies produced may be purified using standard methods and used in assays designed to detect the presence of FIV.

[0021] The nucleic acid, preferably DNA, which has been mutated, may be used in a vaccine in which it is present at a concentration sufficient to induce protective immunity upon administration to a cat. Alternatively, a vaccine may include a host cell transfected with such DNA and, if desired, the host cell may be fixed after viral proteins are expressed. The vaccines may be administered to a cat at a dosage and for a duration sufficient to induce an immune response in a cat, and immunization protocols may be optimized for inducing protective immunity against subsequent infection by FIV-141.

E. Methods of Making and Using Attenuated Lentiviruses

[0022] The methods disclosed herein in connection with the production of attenuated FIV-141 may be effectively applied to the attenuation of other strains of FIV and to other types of lentivirus. A virus that has significantly reduced infectivity relative to its unmutated, wild type counterpart may be made by mutating one or more genes selected from the group consisting of MA, CA, NC, DU, ENV, SU, TMf, CT, Vif, ORF(2), Vifn, Vifc, IN, V3/4, V7/8, and RRE. Mutations should be designed to eliminate or substantially reduce the activity of the gene product. This may be accomplished by deleting the entire gene or by deleting a large (e.g., one fourth) fraction of the entire gene. The invention encompasses the attenuated lentiviruses made using the disclosed methods, host cells infected with these viruses, and methods of inducing antibody production by injecting the attenuated virus into a mammal. The antibodies may be purified from infected mammals and used in immunoassays. Alternatively, the purified antibodies, or antibody-containing serum derived from animals infected with attenuated virus, may be used to treat a mammal for lentivirus infection.

[0023] As used herein, the phrase "induction of protective immunity", and the like, is used broadly to include the induction of any immune-based response in response to vaccination, including either an antibody or cell-mediated immune response, or both, that serves to protect the vaccinated mammal against the particular lentivirus. The terms "protective immunity", "protective response", "protect", and the like, as used herein, refer not only to the absolute prevention of any of the symptoms or conditions in the mammal resulting from infection with the particular lentivirus, but also to any detectable delay in the onset of any such symptoms or conditions, any detectable reduction in the degree or rate of infection by the particular lentivirus, or any detectable reduction in the severity of the disease or any symptom or condition resulting from infection by the particular lentivirus. Vaccine preparations according to the present

invention should be administered at a dosage and for a duration sufficient to reduce one or more clinical signs and viral load associated with the infection of the mammal. When the lentivirus is a strain of FIV, the mammal treated will be a cat and the signs associated with the infection will include immunological abnormalities such as an abnormally low level of CD4⁺ T-lymphocytes or an abnormally elevated number of CD8⁺ T-lymphocytes. Other clinical signs will typically include alopecia, anemia, chronic rhinitis, conjunctivitis, diarrhea, emaciation, enteritis, gingivitis, hematochezia, neurological abnormalities and dermatitis.

[0024] The attenuated lentivirus (*e.g.*, an attenuated strain of FIV), or host cells infected with such a virus, may be used in vaccine at a concentration sufficient to induce immunity when administered to a mammal (*e.g.*, a cat). An immune response may then be induced by administering such a vaccine at a dosage and for a duration sufficient to induce protective immunity against subsequent infection by at least one strain of lentivirus.

F. Methods of Making and Using Mutated Lentivirus Nucleic Acid

[0025] The present invention is also directed to a method of producing a nucleic acid suitable for use in a vaccine against lentivirus, *e.g.* FIV, infection. This is accomplished by reverse transcribing the genomic RNA of the lentivirus; cloning the reverse transcript; mutating one or more genes selected from the group consisting of MA, CA, NC, SU, TMf, ORF(2), CT, ENV, Vif, Vifn, Vifc, V3/4, V7/8, IN, DU, and RRE; and then cloning the mutated nucleic acid. Preferably, mutations should be such that, upon introduction into a host cell, an attenuated virus is made that has significantly reduced infectivity relative to lentivirus produced by the unmutated, wild type nucleic acid. In the case of FIV, infectivity should be reduced or eliminated for feline T-lymphocytes.

[0026] Mutated lentivirus nucleic acid may be purified and used to transfect host cells, make progeny virus, and make antibody in the same way as described above for FIV-141. In addition, the nucleic acid, or host cells transfected with the nucleic acid, may be incorporated into a vaccine and used to induce an protective immunity in a mammal. Preferably, the nucleic acid will encode an attenuated strain of FIV that has significantly reduced infectivity in feline PBMCs, including T-lymphocytes such as FeP2 cells. Under these circumstances, the immune response will be induced in a cat.

Brief Description of the Drawings

[0027] Figure 1: FIV Production from Transfected Cells. Crandell Feline Kidney (CRFK) cells were transfected with a plasmid comprising the full length FIV-141 genome. Beginning at 24 hours post-transfection, cell supernatants were harvested and assayed for the presence of FIV p26 capsid protein using an enzyme immunoassay.

[0028] Figure 2: Infection of FeP2 T Lymphocytes by Co-culture. CRFK cells were grown in six well plates and transfected with plasmid DNA encoding the full length FIV-141 genome. Forty-eight hours after transfection, 2 x 10⁶ FeP2 cells were introduced into each well. Beginning 72 hours after co-cultivation, FeP2 cells were separated and their supernatants were tested for the presence of FIV p26 capsid protein by ELISA.

[0029] Figure 3: Infection of FeP2 Cells by Adsorption. 2 x 10⁶ FeP2 cells were suspended in 200 ul of FIV-141 virus-containing conditioned medium derived from CRFK cells transfected with the full length infectious FIV-141 clone. Beginning at four days post-infection, FeP2 cell supernatants were tested for the presence of FIV-141 virus using a p26 ELISA assay.

[0030] Figure 4: Expression of FIV-141 Viral Protein by Deletion Clones. A variety of clones mutated to delete FIV genes or regulatory regions were made and transfected into CRFK cells. After 48 hours, cell supernatants were assayed for the presence of FIV p26 capsid protein by ELISA. The results for each deletion clone, as well as the wild type FIV-141 molecular clone, are shown.

[0031] Figures 5-10: Infection of FeP2 T Lymphocytes by FIV-141 Mutants. CRFK cells were grown in six well plates and infected with one of three different FIV-141 deletion clones: TMf del, ENV del, or NC del. After 48 hours, FeP2 cells were added to each well and co-cultures were maintained for an additional 72 hours. The FeP2 cells were then separated from the CRFK cells and assayed for the presence of p26 antigen using an ELISA assay. Monitoring of p26 levels was repeated every 34 days and results are shown in Figure 5. The experiment was repeated using: Vifn del, Vifc del and Vif del (Figure 6); MA del and CA del (Figure 7); V3/4 del, V7/8 del and CT del (Figure 8); ORF(2) del (Figure 9); and DU del, SU del, IN del, and RRE del (Figure 10).

Detailed Description of the Invention

A. Production of FIV-141 and DNA Encoding the Virus

[0032] The present invention is directed to a novel strain of feline immunodeficiency virus (designated herein "FIV-141") that is distinguished from all similar strains based upon its genomic nucleic acid sequence and biological functions.

Although the genome of FIV-141 consists of RNA, this is reverse transcribed into DNA and integrated into the genome of an infected host. It will be understood that references made herein to sequences of FIV and to mutated forms of such sequences encompass both the reverse transcribed viral RNA sequences as well as the corresponding DNA itself.

[0033] It is well known that techniques such as site-directed mutagenesis may be used to introduce variations into the structure of nucleic acids. Mutations in the FIV-141 nucleic acid sequence introduced by this or some similar method are encompassed by the invention, provided that at least one major biological characteristic of the resulting virus, *e.g.*, its antigenicity, remains substantially the same as that of the virus from which it was derived. In a preferred though non-limiting embodiment, mutations that detectably reduce the infectivity of FIV-141 compared to that of the wild-type strain fall within the scope of the invention. For example, a specific mutation in the ENV gene is described herein below which produces a virus that replicates, but which shows greatly reduced infectivity. The present invention includes both this mutation and other mutations that result in substantially reduced viral infectivity.

[0034] As discussed in the Examples section, the complete FIV-141 genome has been cloned and a plasmid containing the full length sequence has been deposited as ATCC number 203001. Standard methodology may be used to isolate this plasmid and transfect it into host cells capable of supporting virus production. Crandell feline kidney (CRFK) cells have been found to be suitable for this purpose, but other cell types such as, *e.g.*, feline T lymphocyte cells, may be used as well. In some cases, host cells expressing the virus may be used directly, *e.g.*, they may be harvested and used to generate antibodies or in a vaccine. Alternatively, the virus produced in the cells may be isolated in highly purified form using known separation techniques such as sucrose-gradient centrifugation. Such methods are effective both for the wild type virus and for mutant forms of the virus.

[0035] An alternative method for obtaining the FIV-141 genome is to perform PCR amplification using primers corresponding to sequence elements in SEQ. ID No:1. In general, the primers should be about 20 to 50 bases in length. A strategy may be designed for amplifying the entire FIV-141 genome or, alternatively, portions of the genome may be amplified separately and then joined together to form the full length sequence. The Examples section below describes specific primers and methods that have been found to be effective, but alternative procedures may be developed and used as well.

[0036] If virus is being isolated from a natural source, then primers for PCR should correspond to sequences unique to FIV-141. Successful amplification using such primers will indicate that a virus responsible for an infection is, in fact, FIV-141. Thus, PCR may be used both diagnostically, as well as in methods for isolating virus.

B. Production of Inactivated Virus and Fixed Host Cells

[0037] The FIV-141 virus may be used to generate antibodies in an appropriate host and in vaccines. In either case, it will usually be desirable to inactivate the virus prior to administering it to an animal. Inactivation may be accomplished by any means known in the art. For example, virus may be purified and then inactivated by incubation for about 24 hours in 0.8% formalin or 1.25% paraformaldehyde. Such procedures may be used either with wild type or mutant viruses.

[0038] Antibodies may also be generated or immunizations accomplished using host cells infected with FIV-141 or mutated forms of the virus. Any host cell capable of supporting viral replication may be used including peripheral blood mononuclear cells (PBMCs). Ordinarily, cells should be fixed prior to administration to an animal. Fixing may be performed by treating cells with paraformaldehyde (*e.g.*, 1.25%) for a period of about 24 hours at 37°C. The other methods discussed above for inactivating virus may also be used for fixing cells, as may any other method disclosed in the art.

C. Production of Attenuated Virus

[0039] As discussed above, vaccines may be produced using either inactivated virus or fixed host cells. An alternative method is to use a virus that has been attenuated by mutating one or more genes in the viral genome. The objective is to produce a virus that is not infectious when administered to a cat. Rates of viral replication can be determined *in vitro* by infecting cells (*e.g.*, PBMCs) with virus, and then determining how the levels of virus change with time. Replication can be followed using an immunological assay that measures an antigen specific for FIV, by quantitative PCR, or by measuring the activity of an enzyme specific to the virus (*e.g.*, reverse transcriptase). Infectivity can be determined by exposing feline T lymphocytes (*e.g.*, FeP2 cells) to virus and determining the extent to which the cells take up the virus and support replication (see Example 4 below).

[0040] Mutations in the FIV-141 genome may be made by site-directed mutagenesis. One way to carry this out is to amplify viral genes with primers that introduce alterations into the normal gene sequence. For example, unique restriction sites may be introduced in a selected region of the genome and the sequence between such sites may then be excised by restriction enzyme digestion. After excision, the remaining portion of genomic DNA may be religated and then introduced into an appropriate host cell to produce mutated virus. A detailed description of the making and testing of mutated viruses and mutated viral genomes is provided in Examples 3 and 4 below. A summary of various mutations

that have been introduced may be found in Table 1.

Table 1

Mutations In FIV-141		
MUTATION	NUCLEOTIDES DELETED	AMINO ACIDS DELETED
MA del	123 bases, nucleotides 879-1001	41 amino acids, residues 85-125 at the C-terminus of the MA protein
CA del	114 bases, nucleotides 1056-1169 ,	38 amino acids, residues 9-46 at the N-terminus of the CA protein
NC del	242 bases, nucleotides 1635-1876	21 amino acids in the CA region and 51 amino acids in the NC region, accompanied by a reading frame shift preventing expression of the terminal portion of the NC protein
ENV del	2103 bases deleted, nucleotides 6577-8679	701 amino acids from the middle of the ENV protein, residues 106-806
SU del	1509 bases, nucleotides 6577-8085	503 amino acids of the SU protein, residues 106-608
V3/4 del	432 bases, nucleotides 7339-7770	144 amino acids of the V3 and V4 regions of SU, residues 360-503
V7/8 del	216 bases, nucleotides 8380-8595	72 amino acids from the V7 and V8 variable regions of the TM protein, residues 98-169
TMf del	75 bases, nucleotides 8071-8145	25 amino acids in the cleavage junction between SU and TM
CT del	138 bases, nucleotides 8686-8823	46 amino acids from the cytoplasmic domain of TM
DU del	345 bases, nucleotides 4019-4363	115 amino acids from the DU protein, residues 9-123
IN del	669 bases, nucleotides 4418-5086	223 amino acids of the IN protein, residues 9-231
Vifn del	150 bases, nucleotides 5286-5435	50 amino acids from the N-terminal portion of the Vif protein, residues 19-68
Vifc del	438 bases, nucleotides 5436-5873	146 amino acids from the C-terminal portion of Vif, residues 69-214
Vif del	588 bases, nucleotides 5286-5873	196 amino acids from the Vif protein, residues 19-214
Orf(2) del	237 bases, nucleotides 5988-6224	79 amino acids of the ORF(2) protein
RRE del	84 bases, nucleotides 8827-8910	-

[0041] Examples of several specific mutations that produce attenuated viruses suitable for administration to animals to induce antibody production or for use in vaccines are MA del, ENV del, V3/4 del, V7/8 del, TMf del, CT del, Vif del, Vifc del, Vifn del, ORF(2) del, CA del, NC del, SU del, IN del, DU del, and RRE del. Thus, viruses mutated in any of the Vif, MA, ORF(2), ENV, Vifn, Vifc, V3/4, V7/8, TMf, CT, SU, CA, NC, IN, DU, or RRE genes are attenuated, and other nucleotide deletions or alterations that inactivate these genes should produce viruses with similar characteristics.

D. Generation of Antibodies to FIV-141 and Treatment of Infected Cats

[0042] Antibodies to FIV-141 can be produced in any of the animals typically used for antibody production, including mice, rabbits, *etc.* However, it is preferred that the antibodies be produced in cats. If wild type virus is used as antigen, the virus should be inactivated prior to administration. When attenuated viruses are used, *e.g.*, viruses mutated so as to reduce or eliminate their infectivity, inactivation or the fixing of host cells is not required, although these procedures may be performed if desired.

[0043] Compositions containing virus may be administered to animals by any route, but animals will typically be injected intramuscularly, subcutaneously or intravenously. Generally, the virus preparation will include an adjuvant, *e.*

g., Freund's complete or incomplete adjuvant. Appropriate preparations for injection, injection schedules and the like are well known in the art and may be employed for FIV-141 and its mutants (see, *e.g.*, Harlow, *et al.*, 1988, Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, N.Y.; Klein, 1982, Immunology: The Science of Self-Nonself Discrimination). Monoclonal antibodies may also be used, and can be made using standard procedures (Kennett, *et al.*, 1980, Monoclonal Antibodies and Hybridomas: A New Dimension in Biological Analyses; Campbell, 1984, "Monoclonal Antibody Technology," in: Laboratory Techniques in Biochemistry and Molecular Biology).

[0044] Antibodies or fragments of antibodies reacting with specificity to FIV-141 (*i.e.*, having at least a 100 fold greater affinity for FIV-141 than for any other virus) may also be used in any of a variety of immunoassays. For example, the antibodies may be used to detect FIV-141 in radioimmunoassays or in immunometric assays, also known as "2-site" or "sandwich" assays (see Chard, 1978, "An Introduction to Radioimmune Assay and Related Techniques," in: Laboratory Techniques in Biochemistry and Molecular Biology, North Holland Publishing Co. N.Y.). In a typical immunometric assay, a quantity of unlabeled antibody is bound to a solid support that is insoluble in the fluid being tested, *e.g.*, blood, lymph, cellular extracts, *etc.* After the initial binding of antigen to immobilized antibody, a quantity of detectably labeled second antibody (which may or may not be the same as the first) is added to permit detection and/or quantitation of antigen (see, *e.g.*, Kirkham *et al.* (ed.), 1970, Radioimmune Assay Methods, pp. 199-206, E&S Livingstone, Edinburgh). Many variations of these types of assays are known in the art and may be employed for the detection of FIV.

E. Conventional Vaccines and Vaccination Procedures

[0045] Vaccines and vaccination procedures employing different strains of FIV or closely related viruses have been discussed by a number of authors (Elyar *et al.*, 1997, Vaccine 15:1437-1444; Yamamoto *et al.*, 1993, J. Virol. 67: 601-605; Murphey-Corb *et al.*, 1989, Science 240:1293-1297; Jarrett *et al.*, 1990, AIDS 4:S163-S165; and Desrosiers *et al.*, 1989, Proc. Nat'l Acad. Sci. USA 86:6353-6357). In the case of FIV-141, there are three types of vaccines that may be used: inactivated whole virus vaccine, fixed cell vaccines, and attenuated virus vaccines.

[0046] Typically, a vaccine will contain between about 1×10^6 and about 1×10^8 virus particles in a volume of between about 0.5 and 5 ml. Formulation may take place using standard methods such as those described in Remington's Pharmaceutical Sciences, 1982, Mack Publishing Co., Easton, Pa. 16th ed. Preparations may contain inactivated virus, fixed host cells or attenuated virus, together with a carrier and one or more adjuvants. Vaccines will generally be designed for parenteral administration, although the present invention is compatible with other forms of administration as well. The most preferred vaccines will contain attenuated virus that is completely, or essentially completely, non-infectious when administered to cats.

[0047] Immunization procedures will typically involve several inoculations with vaccine (*e.g.*, 3 inoculations) separated by intervals of 3 to 10 weeks. Procedures for optimizing inoculation schedules and the other parameters associated with immunization are well known in the art.

F. DNA Vaccines

[0048] References describing vaccines and vaccination procedures that utilize nucleic acids (DNA or mRNA) include US Patent 5,703,055, US Patent 5,580,859 and US Patent 5,589,466. Immunogens delivered in this manner typically evoke both a humoral and cytotoxic immune response.

[0049] These procedures may be utilized to produce a vaccine against FIV in which nucleic acid corresponding to attenuated FIV-141 is administered to a cat.

[0050] Either DNA or RNA encoding the attenuated FIV-141 genome may be used in vaccines, but DNA will generally be preferred. The DNA may be present in a "naked" form or it may be administered together with an agent facilitating cellular uptake (*e.g.*, liposomes, or cationic lipids). The typical route of administration will be by intramuscular injection of between about 0.1 and 5 ml of vaccine. The total polynucleotide in the vaccine should generally be between about 0.1 ug/ml and about 5.0 mg/ml. Polynucleotides may be present as part of a suspension, solution or emulsion, but aqueous carriers are generally preferred.

[0051] Immunization of cats using DNA vaccines may be performed as either a single inoculation or as multiple inoculations of divided doses separated, *e.g.*, by intervals of 3 to 10 weeks. If desired, serum may be collected from inoculated animals and tested for the presence of antibodies to FIV-141 or other strains of FIV.

G. Extension of Methodology to Other Lentiviruses

[0052] The methods discussed above for attenuating FIV-141 and for producing mutated viral nucleic acids suitable for use in vaccines may be extended to other strains of FIV and to other types of lentivirus. In each case, the viral genome is cloned and mutated in one or more genes selected from the group consisting of: MA, CA, NC, DU, ENV, SU, TMF, CT, ORF(2), Vif, Vifn, Vifc, V3/4, V7/8, IN, and RRE. The mutation should be designed to inactivate the gene

product. This can usually be most easily accomplished by deleting either the entire gene or a substantial portion of the gene. Although the specific methodology used for inducing mutations will vary depending upon the virus, the basic techniques are routine in the art and, using the procedures disclosed herein as a guide, can be readily carried out by a skilled molecular biologist. Antibody production, the making and administration of vaccines, *etc.*, may be accomplished as discussed in connection with FIV-141 herein, making minor adaptations as needed.

[0053] In addition, it is contemplated that antibodies to certain lentiviruses may be used to provide passive immunity to an animal or human infected with the virus. Either purified antibody or antibody-containing serum may be used for this purpose, and preparations may be administered on a periodic basis until an improvement in one or more signs associated with viral infection is observed.

EXAMPLES

Example 1: Construction of an Infectious FIV Proviral DNA Clone

A. Isolation and Cloning of FIV-141

Virus Isolation

[0054] FIV-141 was isolated from the plasma of an FIV-infected cat. The virus was amplified by administering plasma from the infected animal to a specific pathogen-free (SPF) cat. Infection of the inoculated cat was confirmed by virus isolation and seroconversion. The cat was euthanized 12 weeks post challenge, tissues were collected, and the spleen was used as the source of virus for the molecular cloning of the FIV-141 genome. Genomic DNA was isolated from the infected spleen using a DNA extraction kit (Stratagene, La Jolla, CA) according to the protocol provided by the manufacturer. Purified genomic DNA was dissolved in TE buffer at a concentration of 1 ug/ml and stored at -70°C.

PCR Amplification and Cloning of Three Segments of the FIV-141 Genome

[0055] Three sets of oligonucleotides were designed based upon the published sequences of other FIV isolates (Talbot *et al.*, 1989, Proc. Nat'l Acad. Sci. USA, 86:5743-5747; Miyazawa *et al.*, 1991, J. Virol. 65:1572-1577; Talbot *et al.*, 1990, J. Virol. 64:4605-4613). These oligonucleotides were used to amplify three segments of the FIV-141 genome, one at the 5' end, one at the 3' end and one in the middle of the genome. Because of a low copy number of the FIV proviral genome in infected tissue, two rounds of PCR amplification were performed using a semi-nested set of primers for each segment.

[0056] Three primers were used to clone a segment from the 5' end of the FIV-141 proviral genome, extending from nucleotides 118 to 646. This region covers most of the 5' long terminal repeat, the intervening sequence between the 5' long terminal repeat and the Gag open reading frame, and the N-terminal portion of the Gag gene. The sequences of the primers were as follows: the forward primer pr-1 (117-CCGCAAAACCACAT CCTATGTAAAGCTTGC-146, SEQ ID NO:2) and the two reverse primers, pr-2 (646-CGCCCTGTCCATTCCCATGTTGCTGTAG-617, SEQ ID NO:3) and pr-8 (1047-TTACTGTTTGAATAGGATATGCCTGTGGAG-1018, SEQ ID NO:4). First round PCR amplification was performed using 200 ng each of pr-1 and pr-8 as primers and 1 ug of genomic DNA as template, with a mixture of 0.5 units of *Taq* DNA polymerase (Gibco, BRL Gaithersburg, MD) and 1 unit of *Pfu* DNA polymerase (Stratagene, La Jolla, CA). Amplification proceeded at 94°C for one minute; followed by 30 cycles of denaturing at 94°C, for 45 seconds; annealing at 52°C for 45 seconds; and extension at 72°C for two minutes. The second round amplification was performed using primers pr-1 and pr-2 together with 2 ul of the first round PCR products as template. The same conditions used in the first round of amplification were applied in the second round, except that annealing took place at a temperature of 55°C.

[0057] Three oligonucleotides were also used to clone a segment from the 3' end of the FIV-141 proviral genome. This segment includes nucleotides 8874 to 9367, consisting of most of the 3' long terminal repeat and the intervening sequence between the 3' long terminal repeat and the ENV gene. The sequences of the three primers were as follows: the two forward primers, pr-5 (8793-GCAATGTGGCATGTCTGAAAAAGAGGAGGA-8822, SEQ ID NO:5) and pr-7 (8874-TCTTCCCTTGAGGAAGATATGTCATATGAATCC-8907, SEQ ID NO:6), and the reverse primer, pr-6 (9367-TCTGTGGGAGCCTCAAGGGAGAACTC-9342, SEQ ID NO:7). Primers pr-5 and pr-6 were used to perform the first round amplification, and pr-6 and pr-7 were used to carry out the second round of amplification. The same conditions were applied to the present amplification as those used in the amplification of the segment from the 5' end of FIV-141 described above.

[0058] In order to clone a segment from the middle part of the FIV-141 genome, extending from nucleotides 5147 to 5631 and covering the C-terminal portion of the IN gene and the N-terminal portion of the Vif gene, a first round amplification was performed using the forward primer, pr-3 (4738-ACAAACAGATAATGGACCAAATTTAAAAA-4767,

SEQ ID NO:8) and the reverse primer pr-10 (5631-TTCAATATCATCCACATAAATCCTGT-5604, SEQ ID NO:9). A second round amplification was performed using forward primer pr-9 (5147-TTAAAGGATGAAGAGAAGGGATATT-TCTT-5176, SEQ ID NO:10) and reverse primer-pr-10.

[0059] After the completion of the second round of PCR amplification, the products were applied to a 1% agarose gel and the expected bands for all three regions were purified by a Wizard PCR Preps kit (Promega, Madison, WI). The purified PCR fragments were cloned into PCR-Script Amp SK(+) vectors (Stratagene, La Jolla, CA) according to the procedure recommended by the manufacturer. Inserts were confirmed by restriction enzyme digestion followed by sequencing the two strands of the plasmid DNA (Advanced Genetic Analysis Center, St. Paul, MN). In order to eliminate "errors" in the FIV sequences generated by the DNA polymerases during amplification, three clones from three independent PCR amplifications were sequenced for each region. The consensus sequence from the three independent clones was considered as the authentic FIV-141 sequence.

[0060] Combining the sequences from the 5' and 3' end segments suggests that the long terminal repeat of FIV-141 consists of 354 bases, including 208 bases in the U3 region, 79 bases in the R region and 67 bases in the U5 region. The terminal 2-base inverted repeats, the TATA box, the polyadenylation signal, and a number of putative cis-acting enhancer-promoter elements were perfectly conserved relative to other FIV isolates.

PCR Amplification and Cloning of the Entire Proviral Genome of FIV-141

[0061] Sequence information obtained using the three cloned segments described above was used to design FIV-141 specific primers that could be used to amplify and clone the entire proviral genome in two pieces, the 5' half and the 3' half. Each half was amplified by two rounds of amplification with a semi-nested set of primers.

[0062] To amplify the 5' half of the FIV-141 genome (from nucleotide 1 to 5460), the first round of amplification was performed using forward primer, pr-11 (1-TGGGAAGATTATTGGGATCCTGAAGAAATA-30, SEQ ID NO:11) and the reverse primer pr-10. The amplification protocol followed that provided with the Advantage Genomic PCR Kit from Clontech (Palo Alto, CA). Briefly, the PCR reaction was set up in a total volume of 50 μ l, containing 1 μ l of genomic DNA template (1 μ g/ μ l), 1 μ l of each primer (100 ng/ μ l), 5 μ l of the 10X *Tth* PCR reaction buffer, 2.2 μ l of 25 mM Mg (OAc)₂, 1 μ l of 50X dNTP mix (10 mM each), 1 μ l of 50X Advantage *Tth* Polymerase mix, 1 μ l of *Pfu* polymerase (2.5 U/ μ l), and 36.8 μ l of sterile water. The reaction mix was heated at 94°C for 2 minutes, followed by 30 cycles of amplification: 94°C for 30 seconds and 68°C for 6 minutes. The second round amplification was carried out using 2 μ l of the first round PCR product as template, the same forward primer pr-11 and the reverse primer, pr-12 (5460-CATATC-CTATATAATAATCACGCGTA TGAAAGCTCCACCT-5421, SEQ ID NO:12). To facilitate the construction of a full length FIV-141 genome from the two halves, the restriction enzyme site *Mlu* I (underlined) was incorporated into the primer pr-12. The same PCR conditions as used in the first round amplification were applied in the second round and resulted in the production of an amplification fragment with the size of 5460 base pairs.

[0063] To clone the 3' half of the FIV-141 proviral genome, three primers, pr-9, pr-13 and pr-14, were initially used to perform amplifications. The first round PCR amplification was carried out using forward primer, pr-9 and reverse primer, pr-14 (9464-TGCGAGGTCCCTGGCCCGGACTCC-9441, SEQ ID NO:13). The second round amplification was performed using forward primer, pr-13 (5421-AGGTGGAGCTTTCA TACGCGTGATTATTATAGGATATG-5460, SEQ ID NO: 14) and the same reverse primer pr-14. Primer pr-13 was designed to overlap with pr-12 primer used in the amplification of the 5' half of the genome. As in the pr-12 primer, an *Mlu* I restriction enzyme site (underlined) was incorporated into pr-13 to facilitate the construction of the full-length FIV clone. Unfortunately, after two rounds of PCR amplification, no specific DNA band was observed. It was concluded that the failure to amplify the 3' half of the FIV-141 genome was probably due to the high GC content and very stable secondary structure in primer pr-14. Therefore, a new primer, pr-16 (9444-CTCCAGGGATTGCGAGGTAAGAGAAATTA-9416, SEQ ID NO:15) was designed. This sequence ends 20 bases upstream of the last base in the FIV-141 genome. First round PCR amplification was performed using forward primer pr-9 and reverse primer pr-16. This was followed by amplification using forward primer pr-13 and, again, reverse primer pr-16. A DNA fragment with the expected size was obtained after the second round amplification.

[0064] The DNA fragments of the 5' half and 3' half of the FIV-141 genome were purified using the Wizard PCR Preps DNA purification kit (Promega, Madison, WI), and cloned into pCR-Script Amp SK(+) cloning vectors (Stratagene, La Jolla, CA). Three clones from three independent PCR reactions were sequenced for each of the 5' half and 3' half clones. Both strands of plasmid DNA were sequenced and the authentic consensus sequence for the entire genome was obtained by comparing the results obtained for the three independent clones. The DNASTar program (DNASTar Inc., Madison, WI) was used to perform sequence assembly, comparison and analysis.

B. Molecular Characterization of the Cloned FIV-141 VirusSequence Results and Analysis of the Entire FIV-141 Genome

5 [0065] The entire proviral genome of FIV-141 was found to contain 9464 bases. The genome is organized in a manner typical of lentiviruses and consists of: 5' and 3' long terminal repeats; three large open reading frames (ORF) containing the Gag, Pol, and ENV genes; and three small open reading frames containing the Vif, Rev, and ORF(2) regulatory proteins. The long terminal repeat shares 78.6% and 93.9% sequence homology with FIV-Petaluma (Olmsted *et al.*, 1989, Proc. Nat'l Acad. Sci. USA 86:2448-2452) and FIV-USIL (Sodora *et al.*, 1995, AIDS Res. Hum. Retroviruses 11: 10 531-533) isolates, respectively. The Gag polyprotein shares 88.4% and 94.4% amino acid homology with FIV-Petaluma and FIV-USIL isolates, respectively.

[0066] The Gag gene encodes the matrix (MA) protein (bases 627 to 1031), capsid (CA) protein (bases 1032 to 1724), and nucleocapsid (NC) protein (bases 1725 to 1976). The Gag and Pol polyprotein overlap 97 bases with the Pol ORF, beginning at nucleotide 1880 and ending at nucleotide 5239. A heptanucleotide frameshift signal (5'-GGGAAAC-3') is located 100 bases upstream of the 3' end of the overlap. As the result of a -1 frameshift during translation, a Gag/Pol polyprotein fusion is produced.

[0067] Compared with FIV-Petaluma and FIV-USIL isolates, the Pol polyprotein of FIV-141 exhibits an 85.7% and 92.2% amino acid identity, respectively. The Pol gene encodes: a lead sequence from nucleotide 1880 to 1978; a protease (PR) from nucleotide 1979 to 2326; a reverse transcriptase (RT) from nucleotide 2327 to 3994; a deoxyuridine triphosphatase (DU) from nucleotide 3995 to 4393; and an integrase (IN) from nucleotide 4394 to 5239.

[0068] The Vif ORF overlaps eight bases with the Pol gene, and shares 80.2% and 91.3% amino acid homology with FIV-Petaluma and FIV-USIL isolates, respectively. Immediately following the Vif gene is the ORF(2) gene, beginning at nucleotide 5988 and ending at 6224, which evidences a 62% and 92.4% sequence homology with FIV-Petaluma and FIV-USIL isolates, respectively.

25 [0069] The ENV polyprotein shares a 79.3% and 88.6% amino acid identity with FIV-Petaluma and FIV-USIL isolates, respectively. The ENV gene encodes: a surface (SU) protein, from nucleotide 6262 to 8088; and a transmembrane (TM) protein, from nucleotide 8089 to 8826.

[0070] The Rev protein results from the translation of a multiple splicing mRNA. The first exon of the putative Rev gene apparently shares an initiation codon with the ENV gene, beginning at nucleotide 6262 and ending at 6505. The second Rev exon begins at nucleotide 8947, extends into the U3 region of the 3' long terminal repeat, and ends at nucleotide 9161. The Rev protein of FIV-141 has a 67.3% and 83.9% amino acid homology with FIV-Petaluma and FIV-USIL isolates, respectively. The 151 base Rev responsible element (RRE) overlaps 52 bases with the ENV gene, beginning at nucleotide 8775 and ending at 8925.

35 [0071] Based on the sequence comparisons within the V3 region of the SU glycoprotein, FIV-141 is a type B isolate. Apparently, FIV-141 is most closely related to FIV-USIL, another type B FIV isolate.

C. Construction of a Full-Length Molecular Clone of FIV-141

40 [0072] In order to construct a full-length FIV-141 clone, the 20 bases at the extreme 3' end of the genome had to be added to the 3' half clone. In addition, a consensus sequence was identified by comparing the sequences from three independent clones. Site directed mutagenesis (SDM) was then used to adjust the sequences of the 5' and 3' half clones to match that of the consensus before construction of the full length viral clone.

Addition of Missing 20 Bases at the Extreme 3' End of FIV-141

45 [0073] In order to add the 20 bases to the 3' half clone of FIV-141, the long terminal repeat was first PCR amplified and cloned into a PCR-Script Amp SK(+) cloning vector using the 5' half clone as template and forward primer, PR-21 (5'-TTACAAGAATTCAACTGCAG TGGGAA GATTATTGGGATCCTGAAGAAAT-3', SEQ ID NO:16) and reverse primer, pr-20 (5'-TTCAAGGAGCTCTTTGTCGACAAC TGCGAGGTCCCTGGCCC-3', SEQ ID NO:17). In order to facilitate cloning the PCR fragment, two restriction enzyme sites (underlined), EcoRI and Pst I, were incorporated into the forward primer, PR-21, and two sites (underlined), Sac I and Sal I, were incorporated into the reverse primer, PR-20. The FIV-141 specific sequences in the primers are shown in italics. The resulting clone was sequenced and designated as pCR-LTR. A restriction fragment of pFIV-LTR generated by digestion with Sac I and Nhe I was cloned into one of the 3' half clones of FIV-141. The resulting clone was named pFIV3'-2A-1+ and the presence of the 20 bases at the extreme 55 3' end of FIV-141 was confirmed by nucleotide sequencing.

Construction of Consensus Sequence in the 5' and 3' Half Clones

[0074] In order to establish the consensus sequence in the existing 5' and 3' half clones of the FIV-141 genome, SDM was performed. To introduce sequence changes in the first half of the genome, one of the 5' half clones (designated as "pFIV5'-D-11") was used as template. There were a total of 15 nucleotide changes in pFIV5'-D-11 compared to the consensus sequence. Two changes were located in the 5' non-coding region, A602G and A612G, and seven nucleotide changes in the coding region were silent mutations. The other six changes in the coding region resulted in an amino acid substitution for each change, three in the RT region (an A2890G nucleotide change, resulting in an I to M amino acid substitution; a G3461A change resulting in an E to K substitution; and an G3737A change resulting in an E to K substitution), one in the DU protein (a C4383T change, resulting in a T to I substitution), and two in the IN protein (an A4579G change, resulting in an I to M substitution; and an A5007T change, resulting in a Q to L substitution). Seven oligonucleotides were designed to make the two changes in the non-coding region and six changes in the coding region leading to amino acid substitutions. The oligonucleotides are as follows, with mismatches underlined:

15

Oligo pF-1, designed to repair the A602G and A612G errors: 5'-GATTCGTCG
GGGGACAGCCAACAAGGTAGGAGAGATTCTACAGCAACATGGGG-3'
(SEQ ID NO:18);

20

25

Oligo pF-2, designed to fix the error A2890G: 5'-TCAATATATGGATGATA
TCTATATAGGATCAAATTTAAGTAA-3' (SEQ ID NO:19);

30

Oligo pF-3, designed to repair the error G3461A: 5'-GTGATATAGCTCTAAG
GGCATGTTACAAAATAAGAGAAGAATCCATTATAAGAATAGG-3' (SEQ ID
NO:20);

35

40

Oligo pF-4 was designed to repair the error G3737A: 5'-CGGGCAGATG
GCAGGTAATGGAAATAGAAGGAAGTAATCAAAAAGC-3' (SEQ ID NO:21);

45

Oligo pF-5, designed to repair the error C4383T: 5'-AGAAAGGGATTGG
GTCAACTGGAGTCTTTCTTCATGGGTGGA-3' (SEQ ID NO:22);

50

55

Oligo pF-6, designed to repair the error A4579G: 5'-GGGGGACAATTAAA
GATTGGACCTGGCATATGGCAAATGGACTGTACACAC-3' (SEQ ID NO:
23); and

Oligo pF-7, designed to repair the error A5007T: 5'-GGCTCCTTATGAATTA
TACATACAACAGGAATCATTAGAATACAAGAC-3' (SEQ ID NO:24).

5

[0075] In order to make sequence changes in the 3' half of the genome, the 3' half clone "pFIV3'-2A-1+" was used as a template in performing SDM. There were nine changes in the pFIV3'-2A-1+ clone compared to the consensus sequence. Two nucleotide changes in the coding region were silent. The other seven changes all resulted in an amino acid substitution: one in the Vif protein (T5508C, H to Y); one in the ORF(2) region (A6041T, D to E); three in the SU protein (A6922G, V to I; G7007T, T to R; and A7814G, S to N); one in the TM region (A8405T, I to N); and one in the Rev region (A8976G, E to K). Seven mutagenesis oligonucleotides were designed for repairing these seven amino acid substitutions:

15

Oligo pF-8, designed to repair the error T5508C: 5'-CAAAATAGTTTAAGAT
TGIATGTTTATATAAGCAAT-3' (SEQ ID NO:25);

20

Oligo pF-9, designed to repair the error A6041T: 5'-CAGAAAAGTTAGATAGA
GAAGCAGCTATTAGATTGTTTAT-3' (SEQ ID NO:26);

25

Oligo pF-10, designed to repair the error A6922G: 5'-TAAAAGCAAATGTTA
ATATAAGTATACAAGAAGGACCTAC-3' (SEQ ID NO:27);

30

Oligo pF-11, designed to repair the error G7007T:
5'- AAAAGCTACAAGGCAATGCAGAAGGGGAAGGATATGGAAG-3'
(SEQ ID NO:28);

35

Oligo pF-12, designed to repair the error A7814G: 5'- AGAGGACCTTATTGT
ACAATTTAATATGACAAAAGCAGTGGAAA-3' (SEQ ID NO:29);

45

Oligo pF-13, designed to repair the error A8405T: 5'- CCCTCAATCTGTGG
ACAATGTATAACATGACTATAAAATCA- 3' (SEQ ID NO:30);

50

55

Oligo pF-14, designed to repair the error A8976G: 5'- GACAACGCAGAAGAA
GAAAGAAGAAGGCCTTCAAAAAATT-3' (SEQ ID NO:31).

5

[0076] Single stranded DNA template preparations for both clones, pFIV5'-D-11 and pFIV3'-2A-1+, were made essentially by the protocol provided by the manufacturer (Promega, Madison, WI). Briefly, DNA plasmids of the two clones were transfected into the *E. coli* strain CJ236. Single stranded (SS) DNA was rescued using helper phage R408 and purified by phenol/chloroform extraction. Purified SS DNA was dissolved in TE buffer with its concentration being estimated by running 2 ul samples of template preparations on a 1% agarose gel. Oligonucleotides were phosphorylated according to the protocol provided by the manufacturer (Gibco BRL, Gaithersburg, MD).

10

[0077] Oligonucleotides were annealed to template in a total reaction volume of 30 ul. This contained 0.2 pmol of single-stranded DNA template (pFIV5'-D-11 or pFIV3'-2-A-1+), 4 pmol of each oligonucleotide (*i.e.*, pF-1 to pF-7 for the pFIV5'-D-11 template and pF-8 to pF-14 for the pFIV3'-2-A-1+ template), 3 ul of annealing buffer (0.2 M Tris-HCl, pH 7.4, 20 mM MgCl₂, and 0.5 M NaCl). The mixture was incubated at 85°C for 5 minutes and then gradually cooled to room temperature at a rate of approximately 1°C per minute.

15

[0078] In order to synthesize the complementary DNA strand, the following components were added to the annealing mixture: 3 ul of synthesis buffer (4 mM of each dNTP, 7.5 mM ATP, 175 mM Tris-HCl, pH 7.4, 37.5 mM MgCl₂, 215 mM DTT), 3 ul of T4 DNA ligase (3 U/ul), and 3 ul of the diluted T7 DNA polymerase (0.5 units per ul). The reaction was incubated at 37°C for 3 hours, followed by heat inactivation at 68°C for 10 minutes. Two ul of the SDM reaction mixture were used to transfect *E. coli* DHα-5 competent cells.

20

[0079] For the 5' half clone, pFIV5'-D-11, incorporation of one of the mutagenesis oligonucleotides, PF-5, resulted in an addition of a Hinc II site. A preliminary screening with Hinc II resulted in the identification of four positive mutants that were designated as pFIV5'-D-11/M-4, pFIV5'-D-11/M-22, pFIV5'-D-11/M-28 and pFIV5'-D-11/M-52. These four mutants were completely sequenced to verify the incorporation of the other seven desired mutations. The sequencing results revealed that three of the four clones contained all eight mutations. One clone, pFIV5'-D-11/M-28, had only seven positions that were mutated.

25

[0080] Clone pFIV5'-D-11/M-52 was selected as the 5' half clone to be used to construct the full length FIV-141 clone. For the 3' half clone, pFIV3'-2-A-1+, preliminary screening with BspH I digestion identified 10 mutants in which a BspH I restriction site was eliminated due to the incorporation of the mutagenesis oligonucleotide pF13. Complete sequencing revealed that 8 of the 10 clones contained mutations at all seven desired positions. One of the mutants, "pFIV3'-2-A-1+/M-21," contained all of the 8 changes and was selected to be used as the 3' half clone in constructing the full length FIV-141 clone.

30

Construction of the Full Length FIV-141 Clone

35

[0081] In order to construct the full length FIV-141 clone, a 5.5 kb MluI/XhoI fragment derived from the 5' half clone, pFIV 5'-D-11/M-52, was ligated to the 3' half clone pFIV3'-2-A-1+/M-21, which had been digested with the same two restriction enzymes. The full length ligation product was screened by PCR amplification using a forward primer directed to the 5' half clone and a reverse primer directed to the 3' half clone. The forward primer, pr9, had the sequence: 5'-(5147)-TTAAAGGATGAAGAGAAGGGATATTTCTT-(5176)-3' (SEQ ID NO:10). The reverse primer, pr10, had the sequence: 5'-(5631)-TTTCAATATCATCCACATAAATCCTGT-(5604)3' (SEQ ID NO:9). Positive clones were confirmed by restriction digestion and sequencing. One of the resulting full length clones was designated as "pFIV-141B-1" and selected for characterization both *in vitro* and *in vivo*.

40

Example 2: Demonstration that the Full Length Molecular Clone is Infectious

Transfection

50

[0082] Crandell feline kidney (CRFK) cells were grown in six well plates to a confluency of 40 to 60%. Transfection was accomplished by introducing 2 ug of plasmid DNA and following the basic protocol recommended by Trans IT Polyamine Transfection Reagents (Mirus, Madison, WI). Briefly, 10 ul of TransIT Lt-1 (Panvera) was mixed with 1 ml RPMI 1640 medium and incubated at room temperature for 15 minutes. Two ug of plasmid DNA was added to the RPMI/Lt-1 solution and incubated for another 15 minutes at room temperature. Media was removed from wells, cells were washed once with PBS, and the DNA cocktails were added to the cell monolayers. After incubation at 37°C in a CO₂ incubator for four hours, the DNA cocktails were removed from the wells and 2 ml of RPMI 1650 medium supplemented with 3% fetal serum (FS) was added to each well. Twenty-four hours post-transfection, cell supernatants were

55

assayed for FIV production, reverse transcriptase (RT) activity and viral infectivity.

FIV Production from Transfected CRFK Cells

- 5 [0083] Supernatants from the transfected CRFK cells were harvested on a daily basis after the transfection, and were assayed for FIV capsid protein production using the FIV Antigen Test Kit (IDEXX, Portland, ME), according to the protocol recommended by the manufacturer. This enzyme immunoassay was designed to detect the predominant group-associated antigen of FIV p26 capsid protein. FIV antigen p26 was detected at 24 hours post-transfection (PT), reached a peak at 72 hours PT, and then decreased to background levels at 11 days PT (see Figure 1).
- 10 [0084] In order to confirm virus production from the transfected (CRFK) cells, a reverse transcriptase (RT) activity assay (Boehringer Mannheim, Indianapolis, IN) was performed to detect virion-associated RT activity in the transfected cell supernatants. Briefly, 200 μ l of cell supernatant was harvested and spun 5 minutes in a microfuge to pellet cells and cell debris. Supernatants were centrifuged at 20,000 g for 20 minutes at 4°C in a swinging bucket rotor to pellet FIV virus particles. Viral particle pellets were resuspended in 40 μ l of lysis buffer from the kit, and assays were then
- 15 performed as recommended by the manufacturer. Virus production from transfected cells was demonstrated in cell supernatants 48 hours post-transfection (PT).

Infection of CRFK Cells

- 20 [0085] FIV-141 wild type virus does not infect CRFK cells. In order to determine whether the molecular clone virus exhibits similar behavior, CRFK cells were grown in 6 well plates and inoculated with 200 μ l of p26+ conditioned medium from transfected CRFK cells. After incubation for 2 hours at 37°C, cells were washed once with PBS, and 2 ml of RPMI 1640 medium supplemented with 3% FS was added to each well. Supernatants were then monitored for virus production by FIV p26 ELISA every 3 to 4 days post-transfection. It was found that, similar to the wild type virus, the FIV-141 clone
- 25 does not infect CRFK cells.

Infection of FeP2 Cells by Co-Culture with Transfected CRFK Cells

- 30 [0086] CRFK cells were grown in 6 well plates and transfected as described above. At 48 hours post-transfection, 2×10^6 FeP2 cells were added to each p26+ transfected well. After co-culture of cells for 72 hours, FeP2 cells (non-adherent) were separated from CRFK cells (adherent). The supernatants from the FeP2 cells were harvested and monitored for virus production by FIV p26 ELISA every 3 to 4 days. Four days post co-cultivation, high levels of virus production were demonstrated in the FeP2 cell supernatants (see Figure 2). Virus titer reached a plateau 6 days post-transfection, indicating that the FIV-141 molecular clone virus is infectious in FeP2 cells. The results also suggested
- 35 that infection of CRFK cells is blocked in an early stage of virus infection, *i.e.*, at the time of the entry of virus into cells. [0087] Overall, it was concluded that, upon transfection into CRFK cells, the FIV-141 molecular clone can replicate in the cell, and virus particles released from the cells are infectious for FeP2 T lymphocytes.

Infection of FeP2 Cells by Adsorption

- 40 [0088] FeP2 cells (2×10^6) were suspended in 200 μ l of p26+ conditioned medium obtained from transfected CRFK cells and incubated at 37°C for two hours. Cells were washed with PBS, suspended in 2 ml Opti-MEM medium supplemented with 10% heat inactivated FCS, and incubated at 37°C. Supernatants were harvested and monitored for virus production by FIV p26 ELISA every three to four days. Four days post-infection, virus release from infected FeP2
- 45 cells was detected in the supernatants and reached a peak by three weeks post-infection (Figure 3). The results indicate that productive infection of FeP2 cells by FIV-141 can be achieved through either adsorption or co-culture with transfected CRFK cells. Compared to infection by co-cultivation, virus production reached a plateau much more slowly when infection took place by adsorption (Figures 2 and 3).

50 Example 3: Mutant FIV-141 Clones and Their Use in Vaccines

[0089] In order to develop FIV-141 vaccine candidates, the infectious FIV-141 wild-type clone was used to construct a number of gene-deleted clones. The general criteria for making the mutant clones are:

- 55 1. The deletions or mutations introduced into the FIV-141 genome must be severe enough so that virus infectivity is substantially reduced (attenuated) after the clones are transfected into cultured cells *in vitro* or administered to cats *in vivo*.
2. The deletions or mutations introduced into the FIV-141 genome should not abolish the replication competency

of the viral genome, or the ability to express viral proteins at high levels.

[0090] Other factors to be considered are whether the gene-deleted genome will integrate into host chromosomes, whether defective virus particles will form, and the level of viral structural proteins that will be expressed. Based upon these considerations, a number of genes and elements were targeted for deletion. Because viral genome replication was to be maintained, neither the RT nor PR genes of FIV-141 were mutated.

A. Deletions in the Gag Region

[0091] The Gag polypeptide contains three virion structural proteins, MA, CA and NC. Three gene-deletion clones were constructed with a deletion in each of these proteins.

MA del Mutation

[0092] Site-directed mutagenesis was performed to create two Spe I restriction sites in the C-terminal portion of the MA protein using the 5' half clone pFIV5'-D-11/M-52 as template and the mutagenesis primers: Mpm-1 (5'-AGTAAAGAAATGACATGGCGATTACTAGTTTAA AAGTTTTTGCAGTGGC-3', (SEQ ID NO:32); and Mpm-2 (5'-CCATCTATAAAGAAAGTGG GACTAGTGAAGAAGGACCTCCACAGGC-3', SEQ ID NO:33).

[0093] The Spe I sites introduced by the primers are underlined in the sequences. SDM was performed as discussed previously in order to repair the putative errors in the 5' and 3' half clones. Mutants were screened by Spe I restriction digestion and positive clones were used to construct the deletion clone. Spe I digestion was performed to release the Spe I fragment and the remaining part of the clone was self ligated to create the deletion clones. These were screened by PCR amplification using primer sets flanking the deleted region and confirmation was obtained by nucleotide sequencing. The 5' half clone with the deletion was ligated to the 3' half clone pFIV3'-2A-1+/M-21 to generate the full length clone with the deletion. This clone was named FIV-141 MA deletion clone and contained a deletion of 123 bases from nucleotide 879 to nucleotide 1001, corresponding to 41 amino acids from residues 85 to 125 at the C-terminus of MA.

CA del Mutation

[0094] SDM was performed to create two Spe I sites in the CA region of FIV-141 using the 5' half clone pFIV5'-D-11/M-52 as template and, as primers, Mpca-1 (5'-ATTCAAACAGTAAAT GGAGCAACTAGTTATGTAGCCCTTGATC-CAAAAATG-3', SEQ ID NO:34) and Mpca-2 (5'-ACAGCCTTTTCAGCTAATTTAACTAGTACTGATATGGCTACATTAAHATG-3', SEQ ID NO:35). After deletion of the Spe I restriction fragment, the 5' half clone was ligated to pFIV3'-2A-1+/M-21 to generate the gene-deleted full length clone. This clone has a 114 base pair deletion from nucleotides 1056 to 1169, corresponding to the 38 amino acids from positions 9 to 46 at the N-terminus of the CA protein.

NC del Mutation

[0095] The 5' half clone has unique Sca I and Sma I sites at nucleotides 1635 and 1876 respectively. The clone was digested with Sca I and Sma I to release a 242 base pair fragment. The remaining portion of the 5' half clone was self-ligated and then joined to the 3' half clone to generate the gene-deleted full length clone. The deletion consists of 63 bases (21 amino acid residues) in the CA region, 27 bases (9 amino acid residues) between the CA and NC protein and 152 bases (51 amino acid residues) at the N-terminal portion of the NC protein. The deletion also caused a -1 reading frame shift and, therefore, the C-terminal portion of the NC protein cannot be expressed by this clone.

B. Deletions in the ENV Region

[0096] The ENV precursor glycoprotein is processed into two mature proteins: SU and TM. Six deletion clones were constructed in the ENV region.

ENV del Mutation

[0097] SDM was performed to create two BstE II sites in the ENV region using the 3' half clone pFIV3'-2A-1+/M-21 as template and, as mutagenesis primers, Mpenv-1 (5'-ACTATAGTCTATTACTAACTGGTTACCTGAGATATTTAA-TAAGCCATAG-3', SEQ ID NO:36) and Mpenv-2 (5'-TACTTATATGCTTGCCCTACATTGGGTTACCGTATAAGAA ACT-GTACTAATAAAA-3', SEQ ID NO:37). The BstE II sites in the primer are underlined. After deletion of the BstE II fragment, the self-ligated clone was joined to pFIV5'-D-11/M-52. The resulting clone has a deletion of 2103 bases from

nucleotides 6577 to 8679, corresponding to the middle 701 amino acids of the ENV protein (residues 106 to 806). The N-terminal 105 residues, the majority of which overlaps the first exon of the Rev protein, and the C-terminal 45 residues which overlaps with the Rev responsible element (RRE), were maintained in the deletion clone.

5 SU del Mutation

[0098] Two Spe I sites were generated in the SU region of FIV-141 by SDM using clone pFIV3'-2A-1*/M-21 as template and, as mutagenesis primers, Mpsu-1 (5'-GAGGTATAAAGG TAAACAAAAACTAGTGCCATTCATAT-TATGTTAGCCCTTGC-3', SEQ ID NO:38) and Mpsu-2 (5'-ACTAACTATAGTCTATTTACTAACACTAGTTGAGA-TATTTAATAAGCCAT AGAAAC-3', SEQ ID NO:39). The Spe I fragment was deleted by Spe I digestion followed by self ligation of the large remaining fragment. The resulting clone was ligated to pFIV5'-D-11/M-52. This clone has a deletion of 1509 bases from nucleotides 6577 to 8085, corresponding to a deletion of 503 amino acids (residues 106 to 608) of the SU protein. The clone maintains the N-terminal 105 amino acids of the SU protein.

15 V3/4 del Mutation

[0099] SDM was performed to create two Sph I sites flanking the V3 and V4 region of the SU protein. The clone pFIV3'-2A-1*/M-21 was used as template along with the mutagenesis primers: Mpenv-5 (5'-ATACCGAAATGTGGAT-GGTGGAATCAGGCATGCTATTATAAT AATTGTAAATGGGAAGAAGC-3', SEQ ID NO:40) and Mpenv-6 (5'-GCAC-TATGTACAATTG TTCCTTACAGGCATGCTTCACTATGAAAATAGAGGACCTTAT-3', SEQ ID NO:41). Sph I sites are underlined. After digestion to remove the Sph I fragment, the clone was self-ligated and then joined to pFIV5'-D-11/M-52. This clone contains a deletion of 432 bases from position 7339 to 7770, corresponding to a deletion of 144 amino acids (from residue 360 to 503) of the SU protein, covering the V3 and V4 regions.

25 V7/8 del Mutation

[0100] SDM was used to create two Sph I sites flanking the V7 and V8 region of the TM protein. This was accomplished using the clone pFIV3'-2A-1*/M-21 as template and the mutagenesis primers Mpenv-7 (5'-GAATCAATTCCTTT-GTAAGATCGCATGC AATCTGTGGACAATGTATAACATGACTA-3', SEQ ID NO:42) and Mpenv-8 (5'-GGGAAAATT-GGGTGGGATGGATAGGTAAGATCGCATGCTATTTAAAGGACTTCTTGGT AG-3', SEQ ID NO:43). Sph I sites are underlined. Digestion with Sph I resulted in the elimination of 216 bases from nucleotides 8380 to 8595, and was followed by ligation of the large fragment. The resulting clone was then joined to the 5' half clone pFIV5'-D-11/M-52 to generate "V7/8 del." This contains the deletion of 72 amino acids (from residues 98 to 169) of the TM protein covering the V7 and V8 various regions.

35 TMf del Mutation

[0101] The 3' half clone of FIV-141 has a unique Age I site at nucleotide 8145. SDM was performed to create a second Age I site at position 8071. The 3' half clone was used as template along with the mutagenesis primer, Mpenv-3 (5'-GGAAGAAGTTATGAG GTATACCGGT AAACAAAAAAGGGCC-3', SEQ ID NO:44). A 75-base fragment between the two Age I sites was deleted by restriction enzyme digestion followed by self-ligation of the large restriction fragment. The resulting clone was ligated to the 5' half clone to generate "TMf del." This contains a deletion of 25 amino acids in the cleavage junction between the SU and TM proteins. The deleted amino acids include 6 C-terminal residues of the SU protein (4 of which are basic (either K or R) and required for the processing of the SU/TM cleavage site) and 19 N-terminal residues of the fusion peptide of the TM protein (required for membrane fusion between virion envelope and cell membrane).

CT del Mutation

[0102] SDM was performed to truncate the cytoplasmic tail of the TM protein using the 3' half clone pFIV3'-2A-1*/M-21 as template and the mutagenesis primer, Mpenv-4 (5'-CTACTTATATGCTTGCCTACATTGGTC-GACTGATAGTGAACTGTACTAATAAAATATTGG G-3', SEQ ID NO:45). A Sal I restriction site (underlined) was incorporated into the oligonucleotides by silent mutation to facilitate the screening of mutants. Three tandemly repeated translation stop codons (italicized) were incorporated in the primer right after the transmembrane domain of the TM protein. The resulting clone was ligated to the 5' half clone to generate "CT del." This has a 138-base truncation from nucleotides 8686 to 8823 (corresponding to a truncation of 46 amino acids from the cytoplasmic domain of the TM protein).

C. Deletions in the Pol Region

[0103] The Pol polyprotein consists of four enzymatic proteins: PR, RT, DU, and IN. Two deletion clones were constructed in the Pol region.

5 DU del Mutation

[0104] SDM was performed to create two Spe I sites in the DU region using the 5' half clone pFIV5'-D-11/M-52 as template and, as mutagenesis primers, Mpdu-1 (5'-GATGGTTATAGA AGGTGAAGGAATTACTAGTAAAAGATCA-
10 GAAGATGCAGGATATG-3', SEQ ID NO: 46) and Mpdu-2 (5'-GAAATAATAATGGATTCAGAAAGAGGAACTAGTGGA-
TTTGGGTCAACTGGA GTCTTTTC-3', SEQ ID NO: 47). Spe I sites in the primers are underlined. A deletion of 345
bases from nucleotide 4019 to 4363 was achieved by Spe I digestion followed by self-ligation of the large restriction
fragment. The resulting clone was joined to the clone pFIV3'-2A-1*/M-21 to generate "DU del." The clone contains a
deletion of 115 amino acids corresponding to almost the entire DU protein.

15 IN del Mutation

[0105] Two Spe I sites were created by SDM in the IN region of FIV-141 using pFIV5'-D-11/M-52 as template and
the mutagenesis oligonucleotides, Mpin-1 (5'-CTTCATGGGTGGACAGAATTGAAACTAGTGATTAAATCATGAAAAA-
20 TTCACTCAG-3', SEQ ID NO: 48) and Mpin-2 (5'-GCAATGGGTGTATTATAAAGATCAGACTAGTTAA AAAGTGAAG-
GGACCAATGAGAGTAG-3', SEQ ID NO: 49). Spe I sites in the primers are underlined. After deletion of the Spe I
fragment and self ligation, the resulting clone was joined with pFIV3'-2A-1*/M-21 to generate "IN del." This contains a
deletion of 669 bases from nucleotide 4418 to 5036 corresponding to almost the entire IN protein (223 amino acids,
from residue 9 to 231 of IN).

25 D. Deletions in Regulatory Genes or Elements

[0106] Three regulatory proteins identified in FIV are Rev, Vif and ORF2. A Rev-responsible element has been re-
ported at the 3' end of the FIV genome. Five deletion clones were constructed in these regions.

30 Vifn del Mutation

[0107] A unique Mlu I site was introduced in the middle of the Vif gene in the 5' half clone pFIV 5'-D-11/M-52. SDM
was performed to create a second Mlu I site at the N-terminus of the Vif gene using pFIV3'-D-11/M-52 as template and
the mutagenesis primer, Mpvif-1 (5'-AG AAGACTCTTTGCAGTTCTCCAATGAACGCGTTAGAGTGCCATGTTATA-
35 CATATCG-3', SEQ ID NO: 50). The Mlu I site in the primer is underlined. A restriction fragment of 150 bases from
nucleotide 5286 to 5435 was deleted by Mlu I digestion followed by self ligation of the large fragment. The resulting
deletion clone was joined to pFIV3'-2A-1*/M-21 to generate "Vifn del." This contains a deletion of 50 amino acids (from
residue 19 to 68) at the N-terminal portion of the Vif protein.

40 Vifc del Mutation

[0108] The 3' half clone pFIV3'-2A-1*/M-21 has a unique Mlu I site within the Vif region. A second Mlu I site was
created by SDM at the C-terminus of the Vif protein using pFIV3'-2A-1*/M-21 as template and the mutagenesis primer
45 Mpvif-2 (5'-CGTGTGGCAAAGAGGC TAAACGCGTAGAGGCTGTTGTAATCAG-3', SEQ ID NO: 51). The Mlu I site
in the primer is underlined. After deletion of the Mlu I fragment, the resulting clone was ligated to the 5' half clone
pFIV5'-D-11/M-52 to generate "Vifc del." This contains a deletion of 438 bases from nucleotide 5436 to 5873, corre-
sponding to a deletion of 146 amino acids (from residue 69 to 214) at the C-terminal portion of the Vif protein.

50 Vif del Mutation

[0109] To construct "Vif del," the Xho I/Mlu I restriction fragment of Vifc del was replaced with a 5.3 kb Xho I/Mlu I
fragment of Vifn del. The resulting clone contains a deletion of 588 bases from nucleotide 5286 to 5873, corresponding
to a deletion of 196 amino acids (from residue 19 to 214), almost the entire Vif protein.

55 ORF(2) del Mutation

[0110] Two Mlu I sites were created by SDM at nucleotides 5988 and 6224 (at the N- and C-termini of ORF(2)). This

was accomplished using pFIV3'-2A-1*/M-21 as template and, as mutagenesis primers, Mporf-1 (5'-GTGGACGGGA-GAATTATGAACGCGTGAACATAATC CCACTGTTTAATAAGGTTACAG-3', SEQ ID NO:52) and Mporf-2 (5'-CTACAT-TATC CATAAATACTGCCTAGACGCGTTTCTTTTAAATTTTCATCTGCAG-3', SEQ ID NO: 53). Mlu I sites in the primers are underlined. In addition to the two Mlu I sites created by SDM, there is an Mlu I site at nucleotide 5436 in the clone.

To construct "ORF(2) del," a 5.4 kb Mlu I/Xho I fragment from the 5' half clone pFIV5'-D-11/M-52 was ligated to the large Mlu I/Xho I fragment of the 3' half clone pFIV3'-2A-1*/M-21. A 552 base Mlu I fragment from position 5436 to 5988 was then inserted into the resulting clone. ORF(2) del contains a deletion of 237 bases, covering the entire ORF (2) gene.

RRE del Mutation

[0111] SDM was performed to create two Spe I sites in the RRE region using pFIV3'-2A-1*/M-21 as template and the mutagenesis primers, Mprre-1 (5'-GGCATATCTGAA AAAGAGGAGGAATGAAGTATATCAGACCTGTAGAA-TACA-3', SEQ ID NO:54) and Mprre-2 (5'-GAGGAGGATGTGTCATATGAATCAAATACTAGTCAAAAATAACAGT-AAAATCT ATATTG-3', SEQ ID NO:55). Spe I sites in the primers are underlined. Deletion of the Spe I fragment was achieved by Spe I digestion followed by self ligation of the large fragment. The resulting deletion clone was ligated to pFIV5'-D-11/M-52 to generate "RRE del." This contains a deletion of 84 bases from nucleotide 8827 to 8910.

Example 4 Characterization of the FIV-141 Gene Deletion Clones

A. Viral Protein Expression and/or Defective Virus Production

[0112] Each plasmid of the deletion clones was transfected into CRFK cells as previously described. FIV p26 ELISA assays were performed to detect viral protein expression and/or virus particle production in the transfected cell supernatants. At 48 hours post-transfection, samples from 13 of the constructs were found to produce a strong positive signal comparable to that observed for the wild type FIV-141 molecular clone (see Figure 4). The highest levels of virus particle production were observed for the six deletion clones in the ENV region, including ENV del, TMf del, SU del, CT del, V3/4 del and V7/8 del.

[0113] Comparable levels of virus particle production were obtained for seven other deletion clones, including three deletion clones in the Vif region (Vifn del, Vifc del and Vif del), MA del, DU del, IN del and ORF(2) del. The results indicate that the deletions carried by these 13 clones do not interfere with the formation and release of virus particles from the transfected cells. A relatively weak positive signal was detected for NC del, indicating that deletion in this region affects virus particle assembly or release.

[0114] No virus particle production was detected in the supernatants of cells transfected with CA del or with RRE del. The deletion in the C-terminus of the CA protein may either abolish virus particle formation or result in loss of the epitope recognized by the monoclonal antibody (MAb) used in the p26 ELISA kit. As expected, deletion in the RRE region resulted in a block of the export of unspliced viral RNA from the nucleus to the cytoplasm, leading to either a total lack of, or a dramatic decrease in, the expression of viral structural proteins.

B. Intracellular RT-PCR to Detect Viral RNA Expression

[0115] Intracellular RT-PCR was performed to detect viral RNA expression in the two deletion clones, CA del and RRE del. Plasmid DNA for each clone was transfected into different CRFK cells. Forty-eight hours after transfection, total RNA was isolated from the transfected cells using an RNeasy kit (Qiagen, Chatsworth, CA). The RNA was eluted in 50 ul of DEPC water, and 2 ul of each RNA sample was used to synthesize the first strand of cDNA using Superscript II (Gibco BRL, Gaithersburg, MD).

[0116] A 585 base pair fragment from nucleotides 2958 to 3542 was amplified using as a forward primer Sp-8 (5'-TATTATGGTGGGGATTGAAAC-3', SEQ ID NO:56) and, as a reverse primer, Sp-20 (5'-TAATTAGATTGATCCCCAG-GC-3', SEQ ID NO:57). Two ul of cDNA from each reaction and, as a control, 2 ul of total RNA from each preparation, were used as the template in PCR reactions. Each reaction was performed in a volume of 100 ul using a PCR amplification kit (Gibco BRL, Gaithersburg). The reaction proceeded as follows: 25 cycles at 94°C for 30 seconds; 55°C for 30 seconds; and 72°C for another 30 seconds. Ten ul from each reaction was loaded on a 1% agarose gel. A specific band with the expected size was observed for both CA del and RRE del clones, indicating that viral RNA expression occurred in the cells transfected with these clones. The results suggest that the failure to detect p26 protein expression by ELISA for CA del is probably due to either a failure of virus particle formation or a lack of the epitope recognized by the antibody used in the p26 ELISA assay. For the RRE deletion clone, viral gene expression was demonstrated by intracellular RT-PCR, but no p26 protein expression was detected using the ELISA assay. The discrepancy may reflect a much higher sensitivity of RT-PCR assay when compared to the ELISA.

C. Encapsulation of Viral Genome and RT Enzyme in the Defective Virus Particles

[0117] Transfection of CRFK cells by the majority of the FIV-141 deletion clones resulted in the production and release of defective virus particles. In order to determine whether gene-deleted viral genomes and RT protein were encapsidated into virus particles, virion-associated RT PCR and RT activity assays were performed. Briefly, 48 hours post-transfection, 200 μ l of the supernatant from each transfected CRFK culture were harvested and spun 5 minutes in a microfuge to pellet cells and cellular debris. The virus particles in the supernatants were pelleted by ultracentrifugation at 20,000 g for 20 minutes at 4°C in a swinging bucket rotor. To test for encapsidation, virus pellets were resuspended in 350 μ l RLT buffer from the RNeasy kit, and viral RNA was purified by elution in 50 μ l DEPC water as recommended by the manufacturer. First strand cDNA was made using Superscript II, and PCR amplification was performed as described previously using the Sp-8 and Sp-20 primer set.

[0118] Fourteen of 16 deletion clones showed a specific band after RT-PCR amplification, indicating that transfection of CRFK cells by these clones produced defective virus particles and that the gene-deleted viral genomes were encapsidated. The 14 clones consisted of 6 clones from the ENV region (including ENV del, TMf del, SU del, CT del, V3/4 del, and V7/8 del); 3 clones from the Vif region (Vifn del, Vifc del, and Vif del); 2 clones from the Pol region (DU del and IN del); 2 clones from the regulatory gene/element region (ORF(2) del and RRE del); and 1 clone from the Gag region (MA del). Consistent with the p26 ELISA data, CA del showed a negative signal in the virion-associated RT-PCR assay. The NC protein is required for the packaging of the viral genome into the virion and, as expected, no virion-associated gene-deleted viral RNA genome was detected by RT-PCR for NC del. For RRE del, virion-associated gene-deleted viral RNA was demonstrated to be present but no virus particle production was detected using the p26 ELISA assay. The discrepancy in these results may again reflect a much higher sensitivity of the RT-PCR assay relative to the ELISA.

[0119] For testing encapsidation of the RT (*i.e.* reverse transcriptase) enzyme in defective virus particles, virus pellets were resuspended in 40 μ l of the lysis buffer from the RT ELISA kit, and the assay was allowed to proceed as recommended by the manufacturer. Consistent with data obtained using p26 ELISA assays and virion-associated RT-PCR assays, virion-associated RT activity could be detected for 14 deletion clones, including ENV del; SU del; TMf del; V3/4 del; V7/8 del; CT del; MA del; DU del; IN del; Vifn del; Vifc del; Vif del; ORF(2) del; and NC del. No virion-associated RT activity was detected in the CA or RRE deletion clones.

D. Infectivity of the FIV-141 Gene-Deleted Clones *In Vitro*

[0120] GRFK cells were grown in six well plates and transfected as described previously. Forty-eight hours after transfection, 2×10^6 FeP2 cells were added to each well. After cocultivation of the cells for 72 hours, FeP2 cells were separated from CRFK cells and the supernatants from FeP2 cell cultures were harvested and monitored for virus production using the FIV p26 ELISA assay every 3 to 4 days for a total of 4 to 6 weeks.

[0121] Twelve deletion clones were found to have no significant level of p26 capsid protein expression during the monitoring period. These included: ENV del; TMf del; and NC del (Figure 5); 3 deletion clones from the Vif region (Vifn del; Vifc del; and Vif del) (Figure 6); the MA and CA deletion clones (Figure 7); the V3/4, V7/8 and CT deletion clones (Figure 8); and the ORF(2) deletion clone (Figure 9). The results indicate that deletions introduced into these clones totally abolish the infectivity of the virus in the FeP2 cells. Moderate levels of virus replication were detected for four deletion clones including DU del; SU del; IN del; and RRE del (Figure 10).

E. ConclusionsENV del

[0122] The ENV deletion clone, which has a deletion of 701 amino acids in the middle of the ENV protein (residues 106 to 806), totally lost the ability to infect FeP2 cells. Nevertheless, it maintained the ability to assemble and release defective virus particles, to encapsidate the viral genome, and to reverse transcribe RNA. The primary function of the ENV protein is to mediate virus entry into target cells during the early stage of infection. Deletion of the majority of the ENV protein may block virus entry and, hence, virus infectivity.

TMf del

[0123] The TMf deletion clone, containing a 25 amino acid deletion in the cleavage junction between the SU and TM proteins, is non-infectious in FeP2 cells. The deletion may block the cleavage processing of the ENV precursor protein, and this may result in a failure of viral particles to bind to and enter target cells. It has been reported that removal of the cleavage site of the ENV glycoprotein of FIV results in the expression of an uncleaved ENV precursor protein.

However, the expressed recombinant protein maintains its antigenic properties, as evidenced by its interaction with monoclonal antibodies as determined using Western Blots and radioimmunoprecipitation assays (Rimmelzwaan *et al.*, 1994, J. Gen. Virol. 75:2097-2012). Upon transfection into CRFK cells, the deletion clone produces defective virus particles at a level comparable to a wild type FIV-141 clone. The defective viral genome and RT enzymes were en-

SU del

[0124] SU del had a deletion of 503 amino acids from residue 106 to 608 of the SU protein. It was found to maintain levels of virus particle production approximately equal to that of the wild type clone. Both the gene-deleted viral genome and RT enzyme were encapsidated. However, in contrast to ENV del, cells transfected by SU del produced virus particles that are infectious in the FeP2 cells, although to a much lesser extent than the wild type virus. Thus, it appears that deletion of the SU protein from the FIV-141 genome attenuated the virus. It is believed that FIV binding to cellular receptors, which is the first step in virus infection, is mediated by the SU protein when associated with the TM protein. The mechanism by which the mutant virus binds to and enters target cells is unknown. An alternative pathway for the mutant virus to enter host cells may be responsible for the observed lower infectivity associated with the deletion clone.

V3/4 del and V7/8 del

[0125] One hundred forty-four amino acids from residues 360 to 503 of the SU protein (covering the V3 and V4 variable regions), and 72 amino acids from residues 98 to 169 of the TM protein (encompassing the V7 and V8 regions) were deleted in V3/4 del and V7/8 del respectively. Upon transfection into CRFK cells, each clone produced defective virus at levels similar to that observed for the wild type clone. As with other ENV-related deletion clones, V3/4 del and V7/8 del encapsidated their gene-deleted viral genomes and RT enzymes into virions. The infectivity assay indicated that deletion of the V3 and V4 region of SU, and deletion of the V7 and V8 region in the TM protein, totally abolished virus infectivity in the FeP2 cells. The V3 variable region is the immunodominant domain and has been reported to be involved in multiple functions, including virus tropism, viral pathogenesis, and neutralizing epitopes. It is not presently clear at which step viral infection was blocked in these two deletion clones.

CT del

[0126] The TM protein of FIV has a relatively long cytoplasmic tail (46 amino acids in length). Truncation of this tail in CT del clone resulted in a loss of infectivity of the virus in FeP2 cells. However, truncation had no effect on virus particle formation and encapsidation of the viral genome and RT protein. A specific functional interaction between MA and the TM cytoplasmic tail has been reported for FIV as well as for HIV-1. This interaction has been proposed to be important for the incorporation of the ENV protein into virions. Truncation of the cytoplasmic domain in CT del may eliminate the functional interaction between the MA and TM proteins, thereby blocking the incorporation of ENV.

MA del

[0127] MA del contains a 41 amino acid deletion from residues 85 to 125 at the C-terminus of the MA protein. Upon transfection into CRFK cells, the clone produced defective virus at a level comparable to that produced using the wild type FIV-141 clone. This indicates that deletion at the C-terminus domain has no significant effect on virus particle assembly and release. The gene-deleted viral genome and RT protein were encapsidated in the defective virus particles. When these virus particles were released from transfected CRFK cells, they were non-infectious with respect to FeP2 cells.

CA del

[0128] A deletion of 38 amino acids from residues 9 to 46 at the N-terminus of CA protein abolished viral particle formation, as evidenced by a negative signal in the p26 ELISA assay, the intra-virion RT PCR assay, and the RT activity assay. However, intracellular RT PCR from the transfected CRFK cells demonstrated that the deletion did not block viral RNA expression. Therefore, the failure to detect p26 protein or defective virus production in the supernatants of transfected cells is due to the block in viral particle assembly, not in viral protein expression.

NC del

[0129] The entire NC protein was deleted in the NC del clone. Cells transfected with this clone produced defective

virus at a significantly reduced level compared to the wild type clone, indicating that deletion impaired viral particle assembly or release. It has been reported that the NC protein of HIV-1 is not required for the assembly of virus-like particles. The deletion in the NC clone did not effect the packaging of the RT enzyme into defective virions. As expected, no viral genome was encapsidated in the viral particles.

Vif del, Vifc del and Vifn del

[0130] Three deletion clones were constructed in the Vif gene, *i.e.*, Vifn del, Vifc del, and Vif del. Vifn had a deletion of 50 amino acids at the N-terminal portion of the Vif protein. Vifc had a deletion of 146 amino acids at the C-terminal region of the protein, and Vif del had a deletion of almost the entire Vif protein. All three clones exhibited similar properties. Cells transfected with any of the three clones produced virus particles at a comparable rate to the wild type FIV-141 clone. Both viral genomes and RT enzyme were encapsidated in virions for all three clones. Virions released from CRFK cells transfected by the three clones were non-infectious with respect to FeP2 cells, indicating that Vif is required for virus replication in T lymphocytes.

ORF(2) del

[0131] The entire open reading frame of ORF(2) was deleted in the ORF(2) deletion clone. Cells transfected with the clone assembled and released viral particles at a comparable rate to the wild type clone. Although both viral genome and RT enzyme were packaged in the viral particles, the clone failed to replicate in FeP2 cells, suggesting that the gene product of ORF(2) is required for virus production in these cells.

RRE del

[0132] Eighty-four of the 150 total bases comprising the RRE sequence of FIV were deleted in RRE del. This deletion severely impaired viral structural protein expression and the production of viral particles in transfected cells. No p26 production in the supernatants of transfected CRFK cells was detected. Similarly, no packaged RT activity was measured. These results are in good agreement with the proposal that the RRE sequence is required for the export of unspliced and single-spliced viral RNA from the nucleus to the cytoplasm of cells. However, virion-associated viral genomic RNA was demonstrated to be present by RT PCR and the viral particles were infectious in FeP2 cells, although at a markedly reduced level compared with the wild type FIV-141 clone. Taken as a whole, these results indicate that deletion of the RRE sequence dramatically decreases the expression of viral structural proteins. However, it appears that the deletion did not totally abolish expression, and a trace amount of infectious virion particles was produced by the transfected cells.

IN del

[0133] Almost the entire IN protein was deleted in the IN del clone. Upon transfection into CRFK cells, the clone exhibited a level of viral protein expression and viral particle production comparable to that of the wild type clone. Virion-associated RT PCR and RT activity assays indicated that both viral genomic RNA and RT enzyme were packaged into viral particles. Surprisingly, the virions recovered from the cells transfected with the clone were infectious and could replicate in FeP2 cells, although at a reduced level compared with the wild type virus. Integration is an obligate step required for productive infection of a number of retroviruses, including HIV-1. The data suggest that the IN protein of FIV, in contrast to HIV, may not be an obligate requirement for viral protein expression and viral replication in FeP2 cells.

DU del

[0134] Almost the entire DU gene was deleted in the DU del clone. The product of this gene converts dUTP into dUMP. Deletion of the DU gene in the clone did not affect viral protein expression or viral particle production in transfected CRFK cells. Both viral genome and RT enzyme were encapsidated, and the virions produced from transfected cells were infectious for FeP2 cells. However, the deletion clone replicated in FeP2 at a slower rate than the wild type FIV-141 virus. This indicates that the DU gene is required for maximum replication of the virus. The data is consistent with reports that DU deleted FIV maintains its ability to propagate in T lymphocytes.

Deposit Of Biological Materials

[0135] The following biological materials were deposited with the American Type Culture Collection (ATCC) at 12301 Parklawn Drive, Rockville, MD, 20852, USA, on July 1, 1998, and were assigned the following accession numbers:

	ATCC Accession No.
Viral strain FIV-141	VR-2619
Plasmid pFIV-141-B1	203001

5

[0136] All patents, patent applications, and publications cited above are incorporated herein by reference in their entirety.

10

[0137] The present invention is not to be limited in scope by the specific embodiments described, which are intended as single illustrations of individual aspects of the invention. Functionally equivalent compositions and methods are within the scope of the invention.

15

20

25

30

35

40

45

50

55

Annex to the description

[0138]

5

SEQUENCE LISTING

<110> PFIZER PRODUCTS, INC.

10

<120> Compositions and Methods for Protecting Animals from
Lentivirus-Associated Disease Such as Feline
Immunodeficiency Virus

<130> PC10173A

15

<140> To Be Assigned.

<141> To Be Assigned

<150> 60/097,645

20

<151> 1998-08-24

<160> 57

<170> PatentIn Ver. 2.0 - beta

25

<210> 1

<211> 9464

<212> DNA

<213> Feline immunodeficiency virus

30

<400> 1

35

```

tgggaagatt attgggatcc tgaagaaata gaaaaaatgc taatggactg aggacgtaca 60
taaacaagtg acagatggaa acagctgaat atgactcaat gctagcagct gcttaaccgc 120
aaaaccacat cctatgtaaa gcttgccgat gacgtgtatc ttgctccatt ataagagtat 180
ataaccagtg ttttgtaaaa gcttcgagga gtctctctgt tgagggcttt cgagttctcc 240
cttgaggctc ccacagatac aataaaaaaac tgagctttga gattgaaccc tgtcttgat 300
ctgtgtaatt tctcttacct gcgaatccct ggagtcggg ccagggacct cgagttggc 360
gcccgacag ggacttgaaa aggagtgatt agggaagtga agctagagca atagaaagct 420
gtcaagcaga actcctgcag gccttgtagt gggagcagtt gcagacgctg ctggcagtga 480
gtatctctag tggagcggac ctgagctctg gattaagtca ctgctcacag gcctagataa 540
agattatctg gtgactcttc gcggtcgtc aaaccagggg attcgtcggg ggacagccaa 600
caaggtagga gagattctac agcaacatgg ggaatggaca ggggcgagac tggaaaatgg 660
ccattaagag atgtagtaat gttgctgtag gggtagggag caggagtaaa aaatttgag 720
aaggaaatth tagatgggcc ataaggatgg ctaatgtaac tacaggacga gaacctggtg 780
atataccaga gactttagaa cagctaagat caatcatttg tgacttaca gacagaagag 840
aacaatatgg atctagtaaa gaaattgaca tggcaattac cactttaaaa gtttttcag 900
tggcaggaat tctaaatatg actgtaacta ctgccacagc agctgaaaat atgtatgctc 960
agatgggatt agacaccaga ccatctataa aagaaagtgg gggaaaagaa gaaggacctc 1020
cacaggctta tcctattcaa acagtaaatg gagcaccaca gtatgtagcc cttgatccaa 1080
aaatggtgtc tatttttatg gagaaggcaa gagaggggct aggagtgaa gaagtccaac 1140
tgtggtttac agccttttca gctaatttaa catcaactga tatggctaca ttaattatgt 1200
ccgcacctgg ctgtgcagca gataaagaaa tcctagatga aacactgaaa cagatgacag 1260
ctgagtatga tctgaccat cctcctgatg ggcctagacc gctgccctat ttcactgccg 1320
cagagatcat ggggtagga ttgactcaag aacaacaagc agaaccagag tttgccccag 1380
ccagaatgca gtgtagagca tggatctctg aagcattagg aaagctagcg gccataaaag 1440

```

55

	ccaaatctcc	ccgagcagta	caattgaagc	agggagctaa	agaggactat	tcctcattca	1500
	tagatagact	at ttgctcaa	atagatcaag	agcagaacac	agctgaggta	aagctgtatt	1560
	taaaacaatc	tttgagcata	gcaaatgcta	atccagattg	taagagagcg	atgagtcac	1620
5	ttaaaccaga	aagtacttta	gaagagaaac	tgagagcctg	ccaggaaata	ggatcgccag	1680
	gatacaaaat	gcaactattg	gcagaggctc	ttactagggg	gcaaacagtt	caagcaaaag	1740
	gaccaaggcc	agtatgtttc	aattgtaaaa	aaccaggaca	cctggccaga	caatgtagac	1800
	aagcaaagag	atgtaataaa	tgtggaaaac	ctggtcactt	agctgctaac	tgttggaag	1860
10	gaggtaaaaa	gtccccggga	aacggggcga	tggggcgagc	tgcagcccca	gtaaatcaag	1920
	tgcagcaagt	gataccatct	gcacccccgg	tagaggagaa	attgttagat	atgtaaaacta	1980
	taataaaagt	ggtaccacca	caacttttaga	aaaaagacct	gaaatacaaa	tattcgtaaa	2040
	tgggtatcct	ataaaat ttt	tattagatac	aggagcagat	ataacaattt	taaacagaaa	2100
	agactttcag	atagggaatt	ctatagaaaa	tgggaaacag	aatatgattg	gagtaggagg	2160
15	cggaaagaga	ggaacaaatt	atatcaatgt	gcatttagaa	attagagatg	aaaattataa	2220
	gacacagtgt	atatttgga	atgtgtgtgt	cttgagggat	aattcattaa	tacaaccatt	2280
	attgggaaga	gataacatga	ttaagttcaa	cataagggtg	gtaatggctc	aaatttcaga	2340
	gaaaattcca	atagtaaaag	taagaatgaa	agaccctact	caagggcctc	aggtaaaaca	2400
20	atggccatta	tcaaatgaga	aaattgaagc	tctaactgac	atagtaaaaca	ggttagaaca	2460
	agagggaaaag	gtaaaaagag	ctgatccaaa	taatccttgg	aacactcccg	tatttgcaat	2520
	caagaaaaaag	aatggtaaat	ggagaatgct	catagatttt	agggctccta	ataaattaac	2580
	agacaaaggg	gcagaagttc	agttaggact	ccctcatcct	gctggattac	aattgaaaaa	2640
	acaagtaact	gtattggaca	taggggacgc	atattttact	attcctctag	atccagatta	2700
25	tgctccttat	actgcattta	cactacctag	aaaaaacaat	gcaggaccag	ggaggagata	2760
	catatggtgt	agttttaccac	àaggggtggg	cttgagtcca	ttgatatac	agagtacctt	2820
	agacaatata	ctccaacctt	ttattaaaca	gaatcctgag	ttagatattt	atcaatatat	2880
	ggatgatatac	tatataggat	caaatttaag	taaaaaggaa	cataaactaa	aagtagaaga	2940
	attaagaaaa	ttgttattat	ggtggggatt	tgaaaccccg	gaagataaat	tacaagaaga	3000
30	gcccccttat	aagtggatgg	gctatgaatt	acatccatta	acgtgggtcaa	tacagcaaaa	3060
	gcaattagaa	attccagaga	gaccacatt	aaatgaatta	cagaagttag	caggtaagat	3120
	taactgggct	agtcaaacca	ttccagactt	gagcataaaa	gaactaacta	atatgatgag	3180
	aggagatcaa	aagtttagact	caataagaga	atggacgaca	gaggccaaga	atgaagtgga	3240
35	gaaagctaag	agagcaattg	agacacaggc	acagctagga	tattatgac	ctaactcgaga	3300
	attatatgct	aaattaagtc	ttgtgggacc	acatcaacta	agctatcagg	tgtatcataa	3360
	aaaccagaa	cagatattat	ggtatgggaa	aatgaatagg	cagaagaaaa	aagcagaaaa	3420
	tacttgtgat	atagctctaa	gggcatgtta	caaaataaga	gaagaatcca	ttataagaat	3480
40	aggaaaagaa	ccagtatatg	aaatacctac	atccagagaa	gcttgggaat	caaatctaata	3540
	tagatctcca	tatcttaagg	cctcaccacc	tgagggtgaa	tttatacatg	ctgccttaaa	3600
	tataaaaaga	gctctaagca	tgatacaaga	tgcccctata	ttgggagcag	aaacatggta	3660
	catagatggg	ggaagaaaac	aaggaaaagc	agcaagagca	gcttatttga	cagatacggg	3720
	cagatggcag	gtaatggaaa	tagaagggaag	taatcaaaaa	gcagaagtac	aagctttatt	3780
45	attggcccta	caggcaggac	cagaggaaat	gaatattata	acagattcac	aatatattgt	3840
	gaatattatt	aatcaacaac	cagatttgat	ggaagggaatt	tggcaagaag	tcttagaaga	3900
	aatggaaaag	aaagtagcaa	tctttataga	ttgggtacct	ggacataaag	gtattccagg	3960
	aaataaagag	gtagatgaac	tttgtcaaac	gatgatgggt	atagaagggt	aaggaatatt	4020
	agataaaaaga	tcagaagatg	caggatatga	tttattagct	gcacaagaaa	tacatctctt	4080
50	gcctggggag	gtaagagtag	taccaacaag	aacaaagata	atgttaccta	aaggatattg	4140
	gggattaata	atgggaaaaa	gttcaatggg	aagcaaaagga	ttagatgtat	taggaggagt	4200
	tatagatgaa	ggatatagag	gagaattagg	ggtgataatg	attaacctat	ctaaaaaatc	4260
	aataacatta	tcagaaaaaac	aaaaagtagc	acaattaata	atattacctt	gtaaacatga	4320
55	aagcttacaa	caaggagaaa	taataatgga	ttcagaaaga	ggaagaaagg	gatttgggtc	4380
	aactggagtc	ttttcttcac	gggtggacag	aattgaggaa	gcagaattaa	atcatgaaaa	4440

atttcactca gacccacaat acttaagaac agaatttaat ctaccagaa tagtagcaga 4500
 ggaaataaaa agaaaatgtc ctttatgtag aatcagaggg gaacaagtag ggggacaatt 4560
 aaagattgga cctggcatat ggcaaattgga ctgtacacac tttaattggaa aaataattat 4620
 5 tgtcgcagtg catgtggaat caggcttatt atgggcacag gtaattccac aggagactgc 4680
 agattgtaca gttaaagctc tcatgcaact tatcagtgtc cataatgtta cagaactaca 4740
 aacagataat ggaccaaatt ttaaaaatca gaaaatggaa ggactactaa attatatggg 4800
 cataaaacac aaattaggta taccaggtaa cccacaatca caagcattag tagaaaatgc 4860
 10 taaccacaca ttaaaatctt ggattcaaaa atttctctca gaaacttctt ctttggacaa 4920
 cgcatgggcc ctagccttat actgcctcaa ttttaacaa aggggtagac tagggagaat 4980
 ggctccttat gaattatata tacaacagga atcattaaga atacaagact atttttcaca 5040
 aattccacaa aaattaatga tgcaatgggt gtattataaa gatcagaaaag ataaaaagt 5100
 gaagggacca atgagagtag aatattgggg acaaggatca gtattattaa agaatgaaga 5160
 15 gaagggatat tttcttgtag ctaggagaca cataagaaga gtcccagaac cctgcactct 5220
 tcctgaaggg gatgagtgc gaagattggc aggttaagtag aagactcttt gcagttctcc 5280
 aaggaggagt aaatagtgc atgttatata tatcgaattt acctgaaaca gaacaggcac 5340
 aatataaaaa ggactttaag aaaaggctct tagaaaagga gactggattc atctatagat 5400
 20 taagaaaagc tgaaggaata aggtggagct ttcatacgcg tgattattat ataggatatg 5460
 taagagagat ggtggctggg tctagcctac aaaatagttt aagattgtat gtttatataa 5520
 gcaatccatt gtggcatcag tcataccgct ctggcctgac aaattttaat acagagtggc 5580
 cttttgtaaa tatgtggata aagacaggat ttatgtggga tgatattgaa agccaaaata 5640
 tttgcaaagg aggagagatc tcacatggat ggggacctgg aatggtggga attgtgataa 5700
 25 aagcatttag ctgtggagaa aggaagatac aaattactcc tgtcatgatt ataagaggtg 5760
 agatagaccc acagaaatgg tgtggagatt gttggaatct gatgtgtctt aaatattcac 5820
 ttccaaatac attgcagagg cttgctatgc tggcgtgtgg caaagaggct aaagaatgga 5880
 gaggctgttg taatcagcgt tttgtttctc ctttcagaac accctgtgat ctagaggctg 5940
 tccagaacaa gcctaaaagg aatttattgt ggacgggaga attatgaatg gaagaaataa 6000
 30 tcccactggt taataagggt acagaaaagt tagatagaga agcagctatt agattgttta 6060
 ttttagctta tcaggtagac agatgcagat ttattagaat ttacaatta ttactttgga 6120
 gagatagatt taagtcaatc aattctaaat attgtttatg ctggctgtgc tgcaagtctg 6180
 cttattggcg cttgcaatct acattatcca taaatactgc ctagaaatat ttcttttaat 6240
 35 atttcatctg cagatataaa catggcagag ggaggattta ctcaaatca acaatggata 6300
 gggccagaag aagctgaaga attgttagat tttgatatag ctgtacaaat gaatgaagaa 6360
 ggtccattaa acccaggagt aaaccattt aggggtaccag gaattacctc tcaagaaaag 6420
 gatgattatt gtcagatttt acaacaaaaa ctacaagaat taaagaatga aatcaagag 6480
 gtaaaacttg acgaaaacaa tgcaggtaag tttagaaagg caagatattt aagatattct 6540
 40 gatgagagtg tactaactat agtctattta ctaacaggat atttgagata tttataaagc 6600
 catagaaact taggatcttt aagacatgat atagatatag aagcaccaca acaagagcac 6660
 tataatgata aagaaaaggg tactacttta aatataaagt atgggagaag atgttgtatt 6720
 agcacattac ttctatattt aatcctcttc tcagggatag gaatttggct tggaaacaaa 6780
 45 gcacaagtag tgtggagact ccctccttta gtatgtccag tagatgagac agaaataata 6840
 ttttgggatt gttgggcgcc agaggaacca gcctgtcaag attttctggg aacaatgata 6900
 catttaaaag caaatgttaa tataagtata caagaaggac ctacattggg aaattgggca 6960
 agggaaattt ggtctacatt atttaaaaaa gctacaaggc aatgcagaag ggggaaggata 7020
 tggaagaaat ggaatgagac tataacagga cctaaaggat gtgcaaataa tacctgttat 7080
 50 aatatttcag tagtggtagc tgattatcaa tgttatgtag acagagtaga tacatggctg 7140
 caaggaaaag ttaatatctc actatgtttg acaggaggaa agatgctata taataaaaaat 7200
 acaaaacaat taagtactg tacagatcca ttacaaatac cattaattaa ttacacattt 7260
 ggacctaacc aaactgtat gtggaacaca tctttaatca aagaccctga gataccgaaa 7320
 55 tgtggatggt ggaaccaggc agcctattat aataattgta aatgggaaga agctaattgtg 7380
 acatttcaat gtcaaagatc acaaagtcta ccaggatcat gggtaggag aatctcttca 7440

tggagacaaa gaaacagatg ggagtggagg ccagactttg aaagtgagaa agtaaaaaata 7500
 tcattacaat gtaatagtac aaaaaattta acttttgcaa tgagaagttc aagtgattat 7560
 tatgatgtac aaggagcatg gatagaattt ggatgttata gaaataaatc aagaacccat 7620
 5 acggggagcaa gatttagaat aagatgtaaa tggaatgaag gaaagaatct atctctcatt 7680
 gatacatgtg ggactacttc aaatgtgaca ggagccaacc ctgtagattg tactatgaaa 7740
 acaagcacta tgtacaattg ttccttacaa gatagtttca ctatgaaaat agaggacctt 7800
 attgtacaat ttaatatgac aaaagcagtg gaaatgtata atattgctgg gaattgggtct 7860
 10 tgtacatctg atttaccac aggggtggga tatatgaaat gtaattgtac aaatgccact 7920
 gatggggaga ataaaaatgaa atgccctagg aatcagggtt ttttaagaaa ctggtacaat 7980
 ccagttgcag gactaagaca agctcttatg aagtatcaag tagtaaaaca accagaatat 8040
 ttgggtggtac cggagaaggt tatgaggtat aaaggtaaac aaaaaagggc cgctattcat 8100
 attatgttag cccttgctac ggtgttatct atagctggag caggaaccgg tgccactgct 8160
 15 attgggatgg tgacacacta tcagcaagtt ttggctaccc atcagcaggc attggacaaa 8220
 ataactgagg cactgaaaat aaacaactta aggttaataca ctttagaaca tcaagtatta 8280
 gtgatagggt taaaagtaga ggctatagaa aaattcctat atacagcttt tgctatgcaa 8340
 gaattaggat gtaatcagaa tcaattcttt tgtaagattc ccctcaatct gtggacaatg 8400
 20 tataacatga ctataaatca tactactatg aatcatggaa atataacttt gggagaatgg 8460
 tataatcaaa caaaaagttt acaagaaaaa ttttatgaga taattatgga tatagaacaa 8520
 aataatgtac aagggaaaaa tggaatacaa caattacaaa aatgggaaaa ttgggtggga 8580
 tggataggca aaatccctca atatttaaaa ggacttcttg gtagtgtgtt gggaatagga 8640
 ctaggaaatct tactactact tatatgcttg cctacattag tagattgtat aagaaactgt 8700
 25 actaataaaa tattgggata tacagttatt gcaatgcctg aaatagatga tgaggaagta 8760
 caccatcag tggaattgag gagaaatggc aggcaatgtg gcatatctga aaaagaggag 8820
 gaatgatgga gcatttcaga cctgtagaat acaggagtaa tgctgagctg agttcttccc 8880
 tttgaggagg atgtgtcata tgaatccatt tcaaatcaaa aataacagta aaatctatat 8940
 30 tgtaaggcaa acgaaaaaga caacgcagaa gaagaaagaa gaaggccttc aaaaaattga 9000
 tgctggattt agaggctcga tttaaagcgt tgtttgaaac accttcagct acagaatata 9060
 ctgcagacga gacagaagaa gagactcttg aaaaagaaaa aagggtggac tgggaagatt 9120
 attgggatcc tgaagaaata gaaaaaatgc taatggactg aggacgtaca taaacaagt 9180
 acagatggaa acagctgaat atgactcaat gctagcagct gcttaaccgc aaaaccacat 9240
 35 cctatgtaaa gcttgccgat gacgtgtatc ttgctccatt ataagagtat ataaccagt 9300
 ttttgtaaaa gcttcgagga gtctctctgt tgagggttt cgagttctcc cttgaggctc 9360
 ccacagatac aataaaaaac tgagctttga gattgaacce tgtcttgat ctgtgtaatt 9420
 tctcttacct gcgaatccct ggagtcggg ccagggacct cgca 9464

40 <210> 2
 <211> 30
 <212> DNA
 <213> Feline immunodeficiency virus

45 <400> 2
 ccgcaaaacc acatcctatg taaagcttgc 30

50 <210> 3
 <211> 30
 <212> DNA
 <213> Feline immunodeficiency virus

55 <400> 3
 cgcccctgtc cattccccat gttgctgtag 30

<210> 4
 <211> 30
 5 <212> DNA
 <213> Feline immunodeficiency virus

 <400> 4
 10 ttactgtttg aataggatat gcctgtggag 30

 <210> 5
 <211> 30
 <212> DNA
 15 <213> Feline immunodeficiency virus

 <400> 5
 gcaatgtggc atgtctgaaa aagaggagga 30
 20
 <210> 6
 <211> 34
 <212> DNA
 <213> Feline immunodeficiency virus
 25
 <400> 6
 tttcccttt gaggaagata tgtcatatga atcc 34
 30
 <210> 7
 <211> 26
 <212> DNA
 <213> Feline immunodeficiency virus
 35
 <400> 7
 tctgtgggag cctcaaggga gaactc 26

 <210> 8
 <211> 30
 40 <212> DNA
 <213> Feline immunodeficiency virus

 <400> 8
 45 acaaacagat aatggaccaa attttaaaaa 30

 <210> 9
 <211> 28
 <212> DNA
 50 <213> Feline immunodeficiency virus

 <400> 9
 tttcaatatc atccacata aatcctgt 28
 55
 <210> 10

<211> 30
 <212> DNA
 <213> Feline immunodeficiency virus
 5
 <400> 10
 ttaaaggatg aagagaaggg atattttctt 30
 10
 <210> 11
 <211> 30
 <212> DNA
 <213> Feline immunodeficiency virus
 15
 <400> 11
 tgggaagatt attgggatcc tgaagaaata 30
 20
 <210> 12
 <211> 40
 <212> DNA
 <213> Feline immunodeficiency virus
 25
 <400> 12
 catatcctat ataataatca cgcgtatgaa agtccacct 40
 30
 <210> 13
 <211> 24
 <212> DNA
 <213> Feline immunodeficiency virus
 <400> 13
 tgcgaggtcc ctggcccgga ctcc 24
 35
 <210> 14
 <211> 40
 <212> DNA
 <213> Feline immunodeficiency virus
 40
 <400> 14
 aggtggagct ttcatacgcg tgattattat ataggatatg 40
 45
 <210> 15
 <211> 29
 <212> DNA
 <213> Feline immunodeficiency virus
 50
 <400> 15
 ctccagggat tcgagagtaa gagaaatta 29
 55
 <210> 16
 <211> 49
 <212> DNA

<213> Feline immunodeficiency virus

<400> 16

5 ttacaagaat tcaactgcag tgggaagatt attgggatcc tgaagaaat 49

<210> 17

<211> 42

10 <212> DNA

<213> Feline immunodeficiency virus

<400> 17

15 ttcaaggagc tcttttgtcg acaactgcga ggtccctggc cc 42

<210> 18

<211> 53

<212> DNA

20 <213> Feline immunodeficiency virus

<400> 18

gattcgtcgg gggacagcca acaaggtagg agagattcta cagcaacatg ggg 53

25 <210> 19

<211> 42

<212> DNA

<213> Feline immunodeficiency virus

30 <400> 19

tcaatatatg gatgatattct atataggatc aaattttaagt aa 42

<210> 20

35 <211> 58

<212> DNA

<213> Feline immunodeficiency virus

<400> 20

40 gtgatatagc tctaagggca tgttacaaaa taagagaaga atccattāta agaatagg 58

<210> 21

<211> 46

45 <212> DNA

<213> Feline immunodeficiency virus

<400> 21

50 cgggcagatg gcaggtaatg gaaatagaag gaagtaatca aaaagc 46

<210> 22

<211> 44

<212> DNA

55 <213> Feline immunodeficiency virus

EP 0 997 529 A2

<400> 22
agaaagggat ttgggtcaac tggagtcctt tcttcatggg tgga 44

5 <210> 23
<211> 51
<212> DNA
<213> Feline immunodeficiency virus

10 <400> 23
gggggacaat taaagattgg acctggcata tggcaaattg actgtacaca c 51

15 <210> 24
<211> 49
<212> DNA
<213> Feline immunodeficiency virus

20 <400> 24
ggctccttat gaattataca tacaacagga atcatataaga atacaagac 49

25 <210> 25
<211> 36
<212> DNA
<213> Feline immunodeficiency virus

30 <400> 25
caaaatagtt taagattgta tgtttatata agcaat 36

35 <210> 26
<211> 40
<212> DNA
<213> Feline immunodeficiency virus

40 <400> 26
cagaaaagtt agatagagaa gcagctatta gattgtttat 40

45 <210> 27
<211> 40
<212> DNA
<213> Feline immunodeficiency virus

50 <400> 27
taaaagcaaa tgtaatatata agtatataag aaggacctac 40

55 <210> 28
<211> 40
<212> DNA
<213> Feline immunodeficiency virus

<400> 28
aaaagctaca aggcaatgca gaaggggaag gatattggaag 40

<210> 29
 <211> 44
 5 <212> DNA
 <213> Feline immunodeficiency virus

 <400> 29
 10 agaggacctt attgtacaat ttaatatgac aaaagcagtg gaaa 44

 <210> 30
 <211> 40
 <212> DNA
 15 <213> Feline immunodeficiency virus

 <400> 30
 ccctcaatct gtggacaatg tataacatga ctataaatca 40
 20
 <210> 31
 <211> 40
 <212> DNA
 <213> Feline immunodeficiency virus
 25
 <400> 31
 gacaacgcag aagaagaaag aagaaggcct tcaaaaaatt 40

 <210> 32
 30 <211> 50
 <212> DNA
 <213> Feline immunodeficiency virus

 <400> 32
 35 agtaaagaaa ttgacatggc gattactagt ttaaaagttt ttgcagtggc 50

 <210> 33
 <211> 47
 40 <212> DNA
 <213> Feline immunodeficiency virus

 <400> 33
 45 ccattctataa aagaaagtgg gactagtgaa gaaggacctc cacaggc 47

 <210> 34
 <211> 51
 <212> DNA
 50 <213> Feline immunodeficiency virus

 <400> 34
 attcaaacag taaatggagc aactagttat gtagcccttg atccaaaaat g 51
 55
 <210> 35

EP 0 997 529 A2

<211> 51
 <212> DNA
 <213> Feline immunodeficiency virus
 5 <400> 35
 acagcctttt cagctaattt aactagtact gatatggcta cattaattat g 51
 <210> 36
 10 <211> 50
 <212> DNA
 <213> Feline immunodeficiency virus
 <400> 36
 15 actatagtct atttactaac tggttacctg agatatttaa taagccatag 50
 <210> 37
 <211> 54
 20 <212> DNA
 <213> Feline immunodeficiency virus
 <400> 37
 25 tacttatatg ctgcctaca ttgggttacc gtataagaaa ctgtactaat aaaa 54
 <210> 38
 <211> 54
 <212> DNA
 30 <213> Feline immunodeficiency virus
 <400> 38
 gaggtataaa ggtaaacaaa aaactagtgc cattcatatt atgtagccc ttgc 54
 35 <210> 39
 <211> 58
 <212> DNA
 <213> Feline immunodeficiency virus
 40 <400> 39
 actaactata gtctatttac taacaactag ttgagatat ttaataagcc atagaaac 58
 <210> 40
 45 <211> 62
 <212> DNA
 <213> Feline immunodeficiency virus
 <400> 40
 50 ataccgaaat gtggatggtg gaatcaggca tgctattata ataattgtaa atgggaagaa 60
 gc 62
 <210> 41
 55 <211> 58

EP 0 997 529 A2

<212> DNA
 <213> Feline immunodeficiency virus

5 <400> 41
 gcactatgta caattgttcc ttacaggcat gcttcactat gaaaatagag gaccttat 58

<210> 42
 <211> 56
 10 <212> DNA
 <213> Feline immunodeficiency virus

<400> 42
 15 gaatcaattc ttttgtaaga tcgcatgcaa tctgtggaca atgtataaca tgacta 56

<210> 43
 <211> 61
 <212> DNA
 20 <213> Feline immunodeficiency virus

<400> 43
 gggaaaattg ggtgggatgg ataggtaaga tcgcatgcta tttaaaagga cttcttggtg 60
 25 g 61

<210> 44
 <211> 40
 <212> DNA
 30 <213> Feline immunodeficiency virus

<400> 44
 ggaagaagtt atgaggtata ccggtaaaca aaaaagggcc 40

35 <210> 45
 <211> 62
 <212> DNA
 <213> Feline immunodeficiency virus

40 <400> 45
 ctacttatat gcttgccctac attggtcgac tgatagtga actgtactaa taaaatattg 60
 gg 62

45 <210> 46
 <211> 56
 <212> DNA
 <213> Feline immunodeficiency virus

50 <400> 46
 gatgggttata gaaggtgaag gaattactag taaaagatca gaagatgcag gatatg 56

<210> 47
 55 <211> 59

EP 0 997 529 A2

<212> DNA
 <213> Feline immunodeficiency virus

5 <400> 47
 gaaataataa tggattcaga aagaggaact agtggatttg ggtcaactgg agtcttttc 59

<210> 48
 <211> 57
 10 <212> DNA
 <213> Feline immunodeficiency virus

<400> 48
 15 cttcatgggt ggacagaatt gaaactagtg tattaaatca tgaaaaattt cactcag 57

<210> 49
 <211> 59
 <212> DNA
 20 <213> Feline immunodeficiency virus

<400> 49
 gcaatgggtg tattataaag atcagactag taaaaagtgg aagggaacaa tgagagtag 59

25 <210> 50
 <211> 57
 <212> DNA
 <213> Feline immunodeficiency virus

30 <400> 50
 agaagactct ttgcagttct ccaatgaacg cgttagagtg ccatgttata catatcg 57

35 <210> 51
 <211> 44
 <212> DNA
 <213> Feline immunodeficiency virus

40 <400> 51
 cgtgtggcaa agaggctaaa acgcgtagag gctgttgtaa tcag 44

<210> 52
 <211> 56
 45 <212> DNA
 <213> Feline immunodeficiency virus

<400> 52
 50 gtggacggga gaattatgaa cgcgtagaact aatcccactg ttttaataagg ttacag 56

<210> 53
 <211> 55
 <212> DNA
 55 <213> Feline immunodeficiency virus

<400> 53
 ctacattatc cataaatact gcctagacgc gtttctttta atatttcac tgcag 55
 5 <210> 54
 <211> 54
 <212> DNA
 <213> Feline immunodeficiency virus
 10 <400> 54
 ggcatatctg aaaaagagga, ggaatgaact agtatatcag acctgtagaa taca 54
 15 <210> 55
 <211> 59
 <212> DNA
 <213> Feline immunodeficiency virus
 20 <400> 55
 gaggaggatg tgtcatatga atcaaatact agtcaaaaat aacagtaaaa tctatattg 59
 25 <210> 56
 <211> 22
 <212> DNA
 <213> Feline immunodeficiency virus
 30 <400> 56
 tattatggtg gggatttgaa ac 22
 35 <210> 57
 <211> 22
 <212> DNA
 <213> Feline immunodeficiency virus
 40 <400> 57
 taattagatt tgattcccag gc 22

Claims

- 45 1. Substantially purified FIV-141 virus, wherein said virus has a genomic nucleic acid sequence corresponding to SEQ ID NO:1.
2. A host cell infected with the virus of claim 1.
- 50 3. FIV-141 progeny virus produced in the host cell of claim 2.
4. A whole virus vaccine comprising the FIV-141 virus of claim 1, wherein said virus has been inactivated, and a pharmaceutically acceptable carrier.
- 55 5. A substantially purified nucleic acid molecule having a sequence corresponding to SEQ ID NO:1.
6. The nucleic acid molecule of claim 5, wherein said nucleic acid is DNA.
7. A host cell transfected with the nucleic acid of claim 5.

8. FIV progeny virus produced by the host cell of claim 7.
9. A fixed cell vaccine comprising a host cell infected with the virus of claim 1, or transfected with the nucleic acid of claim 5, wherein said host cell has been fixed, and a pharmaceutically acceptable carrier.
10. An attenuated FIV-141 virus which replicates upon entry into a host cell but which exhibits significantly reduced infectivity to feline T lymphocytes when compared to the wild type FIV-141 virus, wherein said attenuated virus is produced by mutating one or more genes in the FIV-141 genome selected from the group consisting of: Vif, MA, ORF(2), ENV, CA, NC, SU, TMf, CT, IN, DU, V3/4, V7/8, and RRE.
11. The attenuated FIV-141 virus of claim 10, wherein said gene is selected from the group consisting of Vif, MA, ORF(2), and ENV.
12. A host cell infected with the attenuated virus of claim 10 or claim 11.
13. Attenuated FIV-141 virus produced in the host cell of claim 12.
14. An attenuated whole virus vaccine, comprising the virus of either claim 10 or claim 11, and a pharmaceutically acceptable carrier.
15. An attenuated host cell vaccine comprising the host cell of claim 12, and a pharmaceutically acceptable carrier.
16. A substantially purified FIV-141 nucleic acid molecule having a sequence corresponding to SEQ ID NO:1, but wherein said nucleic acid molecule is mutated in one or more genes selected from the group consisting of Vif, MA, CA, NC, SU, TMf, ORF(2), CT, ENV, Vifn, Vifc, IN, DU, V3/4, V7/8, and RRE, such that when the mutated nucleic acid molecule has been introduced into a host cell, the host cell produces an attenuated FIV-141 virus that replicates but has significantly reduced infectivity in peripheral blood mononuclear cells (PBMCs) relative to the wild type FIV-141 virus.
17. The nucleic acid molecule of claim 16, wherein said gene is selected from the group consisting of: MA, Vif, ORF(2), and ENV.
18. The nucleic acid molecule of claim 16 or 17, wherein said nucleic acid is DNA.
19. A host cell transfected with the nucleic acid molecule of claim 16, 17 or 18.
20. FIV progeny virus produced by the host cell of claim 19.
21. A vaccine comprising the nucleic acid molecule of claim 16, 17 or 18 at a concentration sufficient to induce immunity when administered to a cat, and a pharmaceutically acceptable carrier.
22. The vaccine of claim 21, wherein said nucleic acid is DNA.
23. A vaccine comprising a host cell transfected with the nucleic acid molecule of claim 16, 17 or 18, and a pharmaceutically acceptable carrier.
24. The vaccine of claim 23, wherein said host cell has been fixed.
25. A method of making an attenuated lentivirus that replicates in host cells but that has significantly reduced infectivity relative to its wild type counterpart, said method comprising mutating one or more genes of the lentivirus selected from the group consisting of: MA, CA, NC, DU, ENV, SU, TMf, CT, V3/4, V7/8, Vif, Vifn, Vifc, IN, RRE, and ORF(2).
26. The method of claim 25, wherein said one or more genes are selected from the group consisting of MA, ORF(2), and ENV.
27. The method of claim 25 or 26, wherein said lentivirus is a strain of FIV.
28. An attenuated lentivirus produced by the method of claim 25 or claim 26.

29. A host cell infected with the attenuated virus of claim 28.
30. An attenuated whole virus vaccine, comprising the virus of claim 28, and a pharmaceutically acceptable carrier.
- 5 31. An attenuated host cell vaccine, comprising the host cell of claim 29, and a pharmaceutically acceptable carrier.
32. A method of producing a nucleic acid molecule suitable for use in a vaccine against lentivirus infection, comprising
 - (a) reverse transcribing the genomic RNA of the lentivirus to form DNA;
 - 10 (b) cloning the DNA of step (a);
 - (c) mutating one or more genes in the cloned DNA of step (b), wherein said genes are selected from the group consisting of MA, CA, NC, SU, TMF, ORF(2), CT, ENV, V3/4, V7/8, Vif, Vifn, Vifc, IN, DU, and RRE; and
 - (d) cloning the mutated DNA of step (c) or its corresponding RNA;
- 15 wherein the mutated DNA or its corresponding RNA, upon introduction into a host cell, produces an attenuated lentivirus that replicates but that has significantly reduced infectivity relative to the wildtype lentivirus encoded by the unmutated nucleic acid.
33. The method of claim 32, wherein said lentivirus is a strain of FIV, and said attenuated virus replicates but has
20 significantly reduced infectivity in feline T-lymphocytes relative to the wildtype FIV encoded by the unmutated nucleic acid.
34. The method of claim 32 or 33, wherein the one or more genes to be mutated are selected from the group consisting of: MA, ORF(2), and ENV.
25
35. A host cell transfected with a nucleic acid molecule produced by the method of claim 32, 33 or 34.
36. Progeny lentivirus produced by the host cell of claim 35.
- 30 37. A vaccine comprising a nucleic acid molecule produced by the method of claim 32, 33 or 34, which nucleic acid molecule is at a concentration sufficient to induce immunity when administered to a mammal, and a pharmaceutically acceptable carrier.
38. The vaccine of claim 37, wherein the mammal is a cat.
- 35 39. A vaccine comprising the host cell of claim 35, and a pharmaceutically acceptable carrier.
40. A strain of feline immunodeficiency virus having ATCC accession No. VR-2619, and progeny virus prepared therefrom.
40
41. A plasmid designated as pFIV-141-B1, and having ATCC accession No. 203001.
42. A method of inducing the production of antibodies to FIV-141 in an animal, comprising administering to the animal:
45 (a) the virus of claim 1; (b) the host cell of claim 2; (c) the nucleic acid molecule of claim 5; (d) the host cell of claim 7; (e) the attenuated FIV-141 virus of claim 10; (f) the host cell of claim 12; (g) the nucleic acid molecule of claim 16; or (h) the host cell of claim 19.
43. The method of claim 42, wherein any of said viruses are inactivated prior to administration.
- 50 44. The method of claim 42, wherein any of said host cells are fixed prior to administration.
45. The method of any of claims 42, 43 or 44, further comprising isolating said antibodies from said animal.
- 55 46. An antibody produced by the method of any of claims 42, 43, 44 or 45.
47. A method of inducing the production of antibodies to a lentivirus, comprising administering to a mammal: (a) the attenuated virus of claim 28; (b) the host cell of claim 29; or (c) the nucleic acid molecule produced by the method of claim 32.

EP 0 997 529 A2

48. The method of claim 47, wherein said virus is inactivated prior to administration.

49. The method of claim 47, wherein said host cell is fixed prior to administration.

5 **50.** The method of claims 47, 48 or 49, further comprising purifying said antibodies from said mammal.

51. An antibody produced by the method of claim 47, 48, 49 or 50.

10 **52.** A method of inducing an immune response in a cat, comprising administering the vaccine of claim 4, 9, 14, 15, 21, 22, 23, 24, 30, 31, 37, 38 or 39 to said cat at a dosage sufficient to induce protective immunity against subsequent infection with FIV-141.

15 **53.** A method of treating a mammal for lentivirus infection, comprising administering the antibody of claim 51 to said mammal at a dosage sufficient to reduce one or more symptoms associated with said infection.

54. A method of inducing an immune response in a mammal, comprising administering the vaccine of claim 30, 31, 37, 38 or 39 to said mammal at a dosage sufficient to induce protective immunity against subsequent infection with at least one strain of said lentivirus.

20 **55.** The method of claim 54, wherein said mammal is a cat, said lentivirus is a strain of FIV and said vaccine is administered at a dosage sufficient to induce protective immunity against subsequent infection by at least one strain of FIV.

25

30


35

40

45

50

55






FIG. 2





FIG. 3






FIG. 5




FIG. 6





FIG. 7

**FIG. 8**




FIG. 9





FIG. 10



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 0 997 529 A3**

(12) **EUROPEAN PATENT APPLICATION**

(88) Date of publication A3:
22.05.2002 Bulletin 2002/21

(43) Date of publication A2:
03.05.2000 Bulletin 2000/18

(21) Application number: 99306508.5

(22) Date of filing: 18.08.1999

(51) Int Cl.7: **C12N 15/49, C12N 7/00,**
C12N 7/04, C12N 5/10,
A61K 39/21, C07K 14/155,
C07K 16/10

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 24.08.1998 US 97645 P

(83) Declaration under Rule 28(4) EPC (expert
solution)

(71) Applicant: **Pfizer Products Inc.**
Groton, Connecticut 06340 (US)

(72) Inventors:
• **Deng, Ruitang**
Old Lyme, Connecticut 06371 (US)
• **Sheppard, Michael George**
North Stonington, Connecticut 06359 (US)

(74) Representative:
Simpson, Allison Elizabeth Fraser et al
Urquhart-Dykes & Lord,
30 Welbeck Street
London W1G 8ER (GB)

(54) **Feline immunodeficiency virus strain FIV-141 and uses thereof**

(57) The present invention is directed to a novel strain of feline immunodeficiency virus, designated herein as FIV-141, and to attenuated forms of the virus

produced by mutating specific regions of the viral genome. The virus and mutated forms of the virus may be used to induce the production of antibodies to FIV-141, and in vaccines designed to protect cats from FIV.




FIG. 1

EP 0 997 529 A3



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 99 30 6508

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	WO 97 32983 A (UNIV CALIFORNIA) 12 September 1997 (1997-09-12) * the whole document *	1-55	C12N15/49 C12N7/00 C12N7/04 C12N5/10
X	US 5 736 378 A (ELDER JOHN H ET AL) 7 April 1998 (1998-04-07) * the whole document *	10-39, 42-55	A61K39/21 C07K14/155 C07K16/10
X	KIYOMASU T ET AL: "IDENTIFICATION OF FELINE IMMUNODEFICIENCY VIRUS REV GENE ACTIVITY" JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 65, no. 8, August 1991 (1991-08), pages 4539-4542, XP001021181 ISSN: 0022-538X * the whole document *	10-39, 42-55	
X	SODORA D L ET AL: "ANALYSIS OF A FELINE IMMUNODEFICIENCY VIRUS PROVIRUS REVEALS PATTERNS OF GENE SEQUENCE CONSERVATION DISTINCT FROM HUMAN IMMUNODEFICIENCY VIRUS TYPE 1" AIDS RESEARCH AND HUMAN RETROVIRUSES, MARY ANN LIEBERT, US, vol. 11, no. 4, April 1995 (1995-04), pages 531-533, XP001021171 ISSN: 0889-2229 * the whole document *	10-39, 42-55	TECHNICAL FIELDS SEARCHED (Int.Cl.7) C07K C12N
-/--			
-The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 27 November 2001	Examiner Petri, B
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons A : member of the same patent family, corresponding document</p>			

EPO FORM 1503 (03.02 (P04001))



European Patent
Office

LACK OF UNITY OF INVENTION
SHEET B

Application Number
EP 99 30 6508

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. Claims: 1-24, 40-46 (completely); 25-39, 47-55 (all partially)

Substantially purified FIV-141 virus, wherein said virus has a genomic nucleic acid sequence corresponding to Seq. Id. No.:1, and attenuated forms of FIV-141 produced by mutating one or more genes in the FIV-141 genome selected from the group consisting of Vif, Ma, ORF(2), ENV, CA, NC, SU, TMf, CT, IN, DU, V3/4, V7/8, and RRE, host cells, vaccines, and methods relating to it.

2. Claims: 25-39, 47-55 (all partially)

Methods for making attenuated lentivirus, said method comprising mutating one or more genes selected from the group consisting of MA, CA, NC, DU, ENV, SU, TMf, CT, V3/4, V7/8, Vif, Vifn, Vifc, IN, RRE, and ORF(2), attenuated lentivirus strains, host cells, vaccines, and methods of inducing the production of antibodies and immunresponses, as far as relating to lentivirus other than FIV-141 (Seq. Id. No. 1).



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 99 30 6508

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	PHILLIPS T R ET AL: "COMPARISON OF TWO HOST CELL RANGE VARIANTS OF FELINE IMMUNODEFICIENCY VIRUS" JOURNAL OF VIROLOGY, NEW YORK, US, US, vol. 64, no. 10, 1 October 1990 (1990-10-01), pages 4605-4613, XP000676716 ISSN: 0022-538X * the whole document *	10-39, 42-55	
X	PATENT ABSTRACTS OF JAPAN vol. 016, no. 387 (C-0975), 18 August 1992 (1992-08-18) -& JP 04 126085 A (TONEN CORP), 27 April 1992 (1992-04-27) * abstract *	10-39, 42-55	
X	DATABASE EMBL [Online] 20 December 1990 (1990-12-20) retrieved from EBI Database accession no. M25381/M25729 XP002184019 81% identity to Seq. Id. No. 1 * abstract * -& OLMSTED ET AL.: PNAS, vol. 86, pages 8088-8092, XP002067357 * the whole document * -& TALBOTT ET AL.: PNAS, vol. 86, 1989, pages 5743-5747, XP002034203 * the whole document * -& OLMSTED ET AL.: PNAS, vol. 86, 1989, pages 2448-2452, XP000001158 * the whole document *	10-39, 42-55	
<p>--- -/--</p>			<p>TECHNICAL FIELDS SEARCHED (Int.Cl.7)</p>
<p>The present search report has been drawn up for all claims</p>			
Place of search		Date of completion of the search	Examiner
MUNICH		27 November 2001	Petri, B
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03.82 (PUB/C01)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 99 30 6508

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	DATABASE EMBL [Online] 16 March 1992 (1992-03-16) retrieved from EBI Database accession no. X57002 XP002184020 82% identity to Seq. Id. No. 1 * abstract *	10-39, 42-55	
P,X	WO 98 40493 A (RIGBY MARK ALAN ;UNIV GLASGOW (GB); JARRETT JAMES OSWALD (GB); NEI) 17 September 1998 (1998-09-17) * the whole document *	10-39, 42-55	
P,X	WO 99 36511 A (DUBENSKY THOMAS W ;SHERIDAN PHILIP LEE (US); CHIRON CORP (US); HSU) 22 July 1999 (1999-07-22) * the whole document *	10-39, 42-55	
P,X	WO 98 39451 A (UNIV NORTH CAROLINA ;YANG JOO SUNG (US); TOMPKINS MARY B (US); TOM) 11 September 1998 (1998-09-11) * the whole document *	10-39, 42-55	
E	EP 1 074 625 A (PFIZER PROD INC) 7 February 2001 (2001-02-07) * the whole document *	1-55	

The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 27 November 2001	Examiner Petri, B
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1503 03.82 (P04C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 99 30 6508

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

27-11-2001

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9732983	A	12-09-1997	AU 723313 B2	24-08-2000
			AU 2328397 A	22-09-1997
			CA 2247091 A1	12-09-1997
			EP 0885302 A1	23-12-1998
			JP 2000506727 T	06-06-2000
			WO 9732983 A1	12-09-1997
			US 6004799 A	21-12-1999

US 5736378	A	07-04-1998	NONE	

JP 04126085	A	27-04-1992	NONE	

WO 9840493	A	17-09-1998	AU 6736998 A	29-09-1998
			EP 1007687 A1	14-06-2000
			WO 9840493 A1	17-09-1998
			JP 2002501369 T	15-01-2002

WO 9936511	A	22-07-1999	AU 2329599 A	02-08-1999
			CA 2318575 A1	22-07-1999
			EP 1045921 A2	25-10-2000
			WO 9936511 A2	22-07-1999

WO 9839451	A	11-09-1998	US 6331616 B1	18-12-2001
			AU 6445798 A	22-09-1998
			WO 9839451 A1	11-09-1998

EP 1074625	A	07-02-2001	EP 1074625 A2	07-02-2001
			JP 2001025392 A	30-01-2001

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82